




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :			(11) International Publication Number:	WO 98/55468	
C07D 263/32, 413/10, A61K 31/42		A1	(43) International Publication Date:	10 December 1998 (10.12.98)	
(21) International Application Number:	PCT/JP98/02398		(74) Agent:	SEKI, Hideo; Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 (JP).	
(22) International Filing Date:	1 June 1998 (01.06.98)		(81) Designated States:	BR, CA, CN, JP, KR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data:	PO 7132	2 Junc 1997 (02.06.97)	AU		
(71) Applicant (<i>for all designated States except US</i>):	FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).		Published	<i>With international search report.</i>	
(72) Inventors; and					
(75) Inventors/Applicants (<i>for US only</i>):	HATTORI, Kouji [JP/JP]; 1-7-1-915, Sumiregaoka, Takarazuka-shi, Hyogo 665-0847 (JP). OKITSU, Osamu [JP/JP]; 57-2A, Minamienoki-cho, Shinjuku-ku, Tokyo 162-0852 (JP). FUJII, Naoaki [JP/JP]; 15-1-221, Tonomachi, Takatsuki-shi, Osaka 569-1126 (JP). TANAKA, Akira [JP/JP]; 9-10-302, Nakano-cho, Takarazuka-shi, Hyogo 665-0056 (JP). TANIGUCHI, Kiyoshi [JP/JP]; 2-1-28, Minamiochiai, Suma-ku, Kobe-shi, Hyogo 654-0153 (JP). KOYAMA, Satoshi [JP/JP]; 6-10-22, Kitatomigaoka, Nara-shi, Nara 631-0001 (JP). NISHIO, Mie [JP/JP]; 98-3, Houjyo Umeharacho, Himeji-shi, Hyogo 670-0945 (JP).				

(54) Title: OXAZOLE COMPOUNDS USEFUL AS PGE2 AGONISTS AND ANTAGONISTS

(57) Abstract

Azole compounds of formula (I) wherein R¹ is lower alkyl substituted with carboxy, etc., R² is hydrogen or lower alkyl, R³ is aryl, etc., R⁴ is aryl, etc., Q is formula (a), etc., and X is O, NH or S, and its salts, which are useful as medicament.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

DESCRIPTION

OXAZOLE COMPOUNDS USEFUL AS PGE₂ AGONISTS AND ANTAGONISTS5 TECHNICAL FIELD

This invention relates to azole compounds and its salts which are useful as a medicament.

BACKGROUND ART

10 Some azole compounds are known, for example, in WO 95/17393, WO 95/24393 and WO 97/03973.

DISCLOSURE OF INVENTION

15 This invention relates to azole compounds. More particularly, this invention relates to azole compounds and its salts which are useful as prostaglandin E₂ (hereinafter described as PGE₂) agonist or antagonists.


Accordingly, one object of this invention is to provide new and useful azole compounds and its salts.

20 Another object of this invention is to provide processes for production of the azole compounds or its salts.

A further object of this invention is to provide a pharmaceutical composition containing, as an active ingredient, said azole compounds or its salts.

25 Still further object of this invention is to provide use of the azole compounds and its salts for manufacture of medicaments for treating or preventing PGE₂ mediated diseases.

30 The azole compounds of this invention can be represented by the following formula (I) :



35 wherein R¹ is lower alkyl substituted with hydroxy, protected

carboxy or carboxy; carboxy; protected
5 carboxy; carbamoyl; a heterocyclic group;
cyano; hydroxy; halo(lower)alkylsulfonyloxy;
lower alkoxy optionally substituted with
hydroxy or carbamoyl; aryl substituted with
carboxy, protected carboxy, carbamoyl or a
heterocyclic group; or amino optionally
substituted with protected carboxy or lower
alkylsulfonyl,

10 R^2 is hydrogen or lower alkyl,

R^3 is aryl optionally substituted with halogen,

R^4 is aryl optionally substituted with halogen,

15 Q is $-A^1-\text{C}_2\text{H}_4-A^3-$ [in which $-A^1-$ is a single bond or
lower alkylene, C_2H_4 is cyclo(C₅-C₉)alkene,
cyclo(C₃-C₉)alkane, bicyclo(C₆-C₉)alkene or
bicyclo(C₅-C₉)alkane, and $-A^3-$ is a single
bond or lower alkylene], and

X is O, NH or S.

20

The compounds of formula (I) may contain one or more asymmetric centers and thus they can exist as enantiomers or diastereoisomers. Furthermore certain compounds of formula (I) which contain alkenyl groups may exist as cis- or trans-isomers. In each instance, the invention includes both mixtures and separate individual isomers.

The compounds of the formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.

30


The compound of the formula (I) and its salt can be in a form of a solvate, which is included within the scope of the present invention. The solvate preferably include a hydrate and an ethanolate.

Also included in the scope of invention are
35 radiolabelled derivatives of compounds of formula (I) which


are suitable for biological studies, and any form of the crystal of the compound (I).

According to the present invention, the azole compounds (I) or its salt can be prepared by the processes which are illustrated in the following scheme.


Process 1




15 Process 2



Process 3




Process 4




Process 5




Process 6



Process 7



Process 8



5
wherein R¹, R², R³, R⁴, -A¹-, \textcircled{A}_2 , -A³-, Q and X are each as defined above,

R¹_a is lower alkoxy,

R¹_b is halo(lower)alkylsulfonyloxy,

5 R¹_c is protected carboxy,

R¹_d is carboxy,

R¹_e is carbamoyl,

R¹_f is lower alkoxy substituted with carbamoyl,

10 R⁵ is lower alkoxy substituted with carboxy or protected carboxy,



\textcircled{A}_2 _a is cyclo(C₅-C₉)alkene or bicyclo(C₆-C₉)alkene,


\textcircled{A}_2 _b is cyclo(C₅-C₉)alkane or bicyclo(C₆-C₉)alkane, and

15 \textcircled{A}_4 is cyclo(C₅-C₉)alkane or bicyclo(C₆-C₉)alkane, each of which is substituted with hydroxy.

The starting compounds (II-1) and (II-2) or their salts can be prepared according to a similar method described in WO 20 95/17393 or the following process.

Process A





wherein R^1 , R^2 , R^3 , R^4 , $-A_1^{1-}$, A_a^2 , $-A_3^{3-}$, A_4^4 and X are each as defined above,

10 R⁵ is hydrogen or lower alkyl,

R^6 is hydrogen or lower alkyl,

A₅) is cyclo(C₅-C₉)alkane or bicyclo(C₆-C₉)alkane,
each of which has two hydroxy groups at
adjacent carbon atoms, and

15 A₆ is cyclo(C₅-C₉)alkane or bicyclo(C₆-C₉)alkane,
each of which has epoxy group at adjacent
carbon atoms.

In the above and subsequent descriptions of the present specification, suitable examples and illustrations of the various definitions which the present invention includes within the scope thereof are explained in detail as follows.

The term "lower" is intended to mean 1 to 6 carbon atom(s), unless otherwise indicated.

Suitable "lower alkyl" and lower alkyl moiety in the term "halo(lower)alkylsulfonyl" and "lower alkylsulfonyl" may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, t-pentyl, hexyl or the like, preferably one having 1 to 4 carbon atom(s).

Suitable "lower alkylene" may include straight or branched one having 1 to 6 carbon atom(s), such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene and

hexamethylene, preferably one having 1 to 3 carbon atom(s), more preferably methylene.

Suitable "cyclo(C₃-C₉)alkane" may include cyclopropane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, or the like preferably one having 5 to 7 carbon atoms.

Suitable "cyclo(C₅-C₉)alkene" may include cyclopentene, cyclohexene, cycloheptene, cyclooctene, or the like, preferably one having 5 to 7 carbon atoms.

Suitable "bicyclo(C₅-C₉)alkane" may include 10 bicycloheptane (e.g., bicyclo[2.2.1]heptane, etc.), bicyclooctene (e.g., bicyclo[3.2.1]octane, etc.), or the like.

Suitable "bicyclo(C₆-C₉)alkene" may include 15 bicycloheptene (e.g., bicyclo[2.2.1]hept-2-ene, etc.), bicyclooctene (e.g., bicyclo[3.2.1]oct-2-ene, etc.), or the like.

Suitable "aryl" may include phenyl, lower alkylphenyl (e.g., tolyl, ethylphenyl, propylphenyl, etc.), naphthyl or the like.

Suitable "heterocyclic group" may include one containing 20 at least one hetero atom selected from nitrogen, sulfur and oxygen atom, and may include saturated or unsaturated, monocyclic or polycyclic group, and preferable one may be heterocyclic group such as 3 to 6-membered heteromonocyclic 25 group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.), 30 or the like, more preferably tetrazolyl.

Suitable "lower alkoxy" may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, t-pentyloxy, hexyloxy, or the like preferably methoxy.

Suitable "protected carboxy" may include esterified 35 carboxy or the like.

Suitable example of the ester moiety of an esterified carboxy may be the ones such as lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.) which may have at least one suitable substituent(s), for example, lower alkanoyloxy(lower)alkyl [e.g., acetoxymethyl, butyryloxymethyl, valeryloxymethyl, pivaloyloxymethyl, etc.], halo(lower)alkyl (e.g., 2-iodoethyl, 2,2,2-trichloroethyl, etc.); lower alkenyl (e.g., vinyl, allyl, etc.); lower alkynyl (e.g., ethynyl, propynyl, etc.); ar(lower)alkyl which may have at least one suitable substituent(s) (e.g., benzyl, 4-methoxybenzyl, 4-nitrobenzyl, phenethyl, trityl, etc.); aryl which may have at least one suitable substituent(s) (e.g., phenyl, toyl, 4-chlorophenyl, tert-butylphenyl, xylyl, mesityl, cumenyl, etc.); phthalidyl; or the like.

Suitable "halo" group in the term of "halo(lower)alkylsulfonyl" may include fluoro, chloro, bromo, iodo, or the like.

Suitable "halo(lower)alkylsulfonyloxy" may include trifluoromethanesulfonyloxy, or the like.

Preferred embodiments of the azole compounds (I) are as follows :

R¹ is lower alkyl substituted with carboxy; carboxy; protected carboxy; carbamoyl; a heterocyclic group; lower alkoxy substituted with carbamoyl; aryl substituted with carboxy, carbamoyl or a heterocyclic group; or amino optionally substituted with lower alkylsulfonyl (more preferably lower alkyl substituted with carboxy; carboxy; carbamoyl; tetrazolyl; lower alkoxy substituted with carbamoyl; aryl substituted with carboxy or carbamoyl),

R² is hydrogen or lower alkyl,

Q is $-A^1 - \text{C}(=O) - A^3 -$ [in which $-A^1-$ is a single bond or

lower alkylene (more preferably methylene),
A₂ is cyclo(C₅-C₉)alkene, cyclo(C₃-C₉)alkane or
bicyclo(C₆-C₉)alkene, bicyclo(C₅-C₉)alkane (more
preferably cyclo(C₅-C₇)alkene, cyclo(C₅-C₇)alkane,
bicyclo[2.2.1]heptane or bicyclo[2.2.1]heptane), and
-A³- is a single bond or lower alkylene (more preferably
single bond)], and

X is O.

The processes for preparing the object and starting
compounds of the present invention are explained in detail in
the following.

Process 1

The compound (I-1) or its salt can be prepared by
subjecting the compound (II-1) or its salt to dehydrating
reaction.

Suitable dehydrating reagent to be used in this reaction
is, for example, an organic acid, such as tolensulfonic acid
(e.g., p-toluenesulfonic acid, etc.) and so on, and an
inorganic acid such as hydrochloric acid, sulfuric acid and so
on.

This reaction is usually carried out in a solvent such
as toluene, acetonitrile, benzene, N,N-dimethylformamide,
tetrahydrofuran, methylene chloride, ethylene chloride,
chloroform or any other solvent which does not adversely
affect the reaction.

The reaction temperature is not critical and the
reaction is usually carried out under cooling to warming.

Process 2

The compound (I-2) or its salt can be prepared by
subjecting the compound (I-1) or its salt to reduction.

The present reduction is carried out by chemical
reduction, catalytic reduction, or the like.

Suitable reducing agents to be used in chemical reduction are a combination of metal [e.g., tin, zinc, iron, etc.] or metallic compound [e.g., chromium chloride, chromium acetate, etc.] and an organic or inorganic acid [e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.], or the like.

Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalyst [e.g., platinum, 10 platinum black, platinum oxide, etc.], palladium catalyst [e.g., palladium black, palladium oxide, palladium on carbon, etc.], nickel catalyst [e.g., reduced nickel, nickel oxide, Raney nickel, etc.], cobalt catalyst [e.g., reduced cobalt, Raney cobalt, etc.], iron catalyst [e.g., reduced iron, Raney 15 iron, etc.], copper catalyst [e.g., reduced copper, Raney copper, Ullman copper, etc.] or the like.

The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, an alcohol [e.g., methanol, ethanol, propanol, etc.], N,N-dimethylformamide, or a mixture thereof.

Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent. Further, a suitable solvent to be used in catalytic reduction may be the above-mentioned solvent and other conventional solvent such as diethyl ether, methylene chloride, dioxane, tetrahydrofuran, etc., or a mixture thereof.

The reaction temperature of this reduction is not critical and the reaction is usually carried out under 30 cooling to warming.

Process 3

The compound (I-4) or its salt can be prepared from the compound (I-3) or its salt by subjecting to (i) the cleavage 35 of ether bond of lower alkoxy group followed by (ii) halo-

(lower)alkylsulfonylation reaction.

(i) Cleavage of ether bond

The cleavage of ether bond is carried out in the presence of an acid including the Lewis acid (e.g., hydrochloric acid, hydrobromic acid, hydroiodic acid, borontribromide, etc.), tri(lower)alkylsilyl iodide, (e.g., trimethylsilyl iodide, etc.) or any other reagent ordinary employed in the field of organic synthesis.

This reaction is usually carried out in a solvent such as toluene, acetonitrile, benzene, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, ethylene chloride, chloroform or any other solvent which does not adversely affect the reaction.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

(ii) Halo(lower)alkylsulfonylation

Suitable reagent to be used in the halo(lower)alkylsulfonylation is, for example, halo(lower)alkylsulfonyl chloride, halo(lower)alkylsulfonic anhydride (e.g., trifluoromethanesulfonic anhydride, etc.) or the like. This reaction is preferably carried out in the presence of base.

Suitable base may include the inorganic base such as alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), alkaline earth metal hydroxide (e.g., magnesium hydroxide, calcium hydroxide, etc.), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), alkaline earth metal carbonate (e.g., magnesium carbonate, calcium carbonate, etc.) or the like, and the organic base such as tri(lower)alkylamino (e.g., trimethylamine, diisopropylethylamine, etc.), pyridine or the like.

This reaction is usually carried out in a solvent such as toluene, acetonitrile, benzene, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, ethylene chloride, chloroform or any other solvent which does not adversely

affect the reaction.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

5 Process 4

The compound (I-5) or its salt can be prepared by reacting the compound (I-4) or its salt with carbon monoxide in the presence of catalytic amount of Palladium-catalyst and base.

10 Suitable Palladium-catalyst may be Palladium(II) acetate, Palladium(II) chloride, or the like.

Suitable base may include the inorganic base such as alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, etc.), alkaline earth metal hydroxide (e.g., calcium hydroxide, etc.), alkali metal carbonate (e.g., sodium carbonate, potassium carbonate, etc.), alkaline earth metal carbonate (e.g., magnesium carbonate, calcium carbonate, etc.) or the like, and the organic base such as tri(lower)alkylamino (e.g., trimethylamine, diisopropylethylamine, etc.), pyridine or the like.

This reaction can be preferably carried out in the presence of a ligand, such as tri(lower)alkylphosphin (e.g., trimethylphosphine, triethylphosphine, etc.), triarylphosphine (e.g., triphenylphosphine, etc.), bis(diarylphosphino)alkane (e.g., 1,3-bis(diphenylphosphino)-propane, or the like.

This reaction is usually carried out in a solvent such as toluene, acetonitrile, benzene, N,N-dimethylformamide, tetrahydrofuran, dimethylsulfoxide, methylene chloride, ethylene chloride, chloroform or any other solvent which does not adversely affect the reaction.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

35 Process 5

The compound (I-6) or its salt can be prepared by subjecting the compound (I-5) or its salt to deesterification.

5 Suitable method of this reaction may include conventional one such as hydrolysis, reduction or the like.

(i) For Hydrolysis :

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

10 Suitable base may include an inorganic base and an organic base such as an alkali metal [e.g., sodium, potassium, etc.], the hydroxide or carbonate or bicarbonate thereof, or the like.

15 Suitable acid may include an organic acid [e.g., formic acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, etc.] and an inorganic acid [e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.]. The deesterification using Lewis acid such as trihaloacetic acid [e.g., trichloroacetic acid, trifluoroacetic acid, etc.] or the like is preferably carried out in the presence of cation trapping agents [e.g., anisole, phenol, etc.].

20 The reaction is usually carried out in a solvent such as water, an alcohol [e.g., methanol, ethanol, etc.], methylene chloride, tetrahydrofuran, 1,2-dimethoxyethane, a mixture thereof or any other solvent which does not adversely influence the reaction. A liquid base or acid can be also used as the solvent. The reaction temperature is not critical and the reaction is usually carried out under 30 cooling to warming.

(ii) For reduction :

Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.

35 Suitable reducing agents to be used in chemical

reduction are a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic or inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).

Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, etc.), copper catalysts (e.g., reduced copper, Raney copper, Ullman copper, etc.) or the like. The reduction is usually carried out in a conventional solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, ethyl acetate, N,N-dimethylformamide, tetrahydrofuran, or a mixture thereof. Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent.

The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.

Process 6

The compound (I-7) or its salt can be prepared by reacting the compound (I-6) or its reactive derivative at the carboxy group, or its salt, with the compound (III) or its reactive derivative, or its salt.

Suitable reactive derivative of the compound (III) may include Schiff's base type imino or its tautomeric enamine

type isomer formed by the reaction of the compound (III) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (III) with a silylating reagent such as

5 N,O-bis(trimethylsilyl)acetamide, N-trimethylsilylacetamide, or the like.

Suitable reactive derivative of the compound (I-6) may include an acid chloride, an acid anhydride, an activated amide, an activated ester, or the like.

10 Suitable acid anhydride may be a symmetric anhydride or a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.),
15 dialkylphosphorous acid, sulfuric acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), alkylcarbonic acid, aliphatic carboxylic acid (e.g., pivalic acid, pentanoic acid, isopentanoic acid, etc.); aromatic carboxylic acid (e.g.,
20 benzoic acid, chlorobenzoic acid, fluorobenzoic acid, nitrobenzoic acid, etc.), or the like.

Suitable activated amide may be imidazolylamide, 4-substituted imidazolylamide, dimethylpyrazolylamide, triazolylamide, tetrazolylamide, or the like.

25 Suitable activated ester may be dimethylinominomethyl $[(\text{CH}_3)_2\overset{+}{\text{N}}=\text{CH}-]$ ester, vinyl ester, propargyl ester, 4-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, methanesulfonylphenyl ester, phenyl thioester, p-nitrophenyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, 8-quinolyl thioester, an activated ester with a N-hydroxy compound (e.g., N,N-dimethylhydroxylamine, 1-hydroxy-
30 2H-pyridone, N-hydroxysuccinimido, N-hydroxybenzotriazole, N-hydroxyphthalimide, etc.), or the like.

35 These reactive derivatives can optionally be selected

from them according to the kind of compound (I-6) to be used.

When the compound (I-6) is used in free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of condensing agent.

5 Suitable condensing agent may include a carbodiimide (e.g., N,N'-dicyclohexylcarbodiimido, N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimido, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimido or its hydrochloride) diphenylphosphinic azido, diphenylphosphinic chloride, 10 diethylphosphoryl cyanide, bis(2-oxo-3-oxazolidinyl)-phosphinic chloride, N,N'-carbonyldiimidazole, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, cyanuric chloride, or the like.

15 The reaction may be also carried out in the presence of organic or inorganic base such as alkali metal carbonate, tri(lower)alkylamine, pyridine, N-(lower)alkylmorphorine, or the like.

20 The reaction is usually carried out in a conventional solvent such as water, acetone, alcohol [e.g., methanol, ethanol, isopropyl alcohol, etc.], tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N,N-dimethylformamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.

25 The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

Process 7

30 The compound (I-7) or its salt can be prepared by reacting the compound (I-5) or its salt with the compound (III) or its salt.

35 The reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, methylene dichloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other

organic solvent which does not adversely affect the reaction.

The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

5 Process 8

The compound (I-8) or its salt can be prepared by reacting the compound (II-2) or its reactive derivative at the carboxy group, or its salt, with the compound (III) or its reactive derivative, or its salt.

10 This reaction can be carried out in a similar manner to that of Process 6 or Process 7, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process 6 and Process 7.

15

Process A

The compound (II-1) or (II-2), or its salt, can be prepared from the compound (V) or its salt according to the methods disclosed in the Preparation 1 to 7 or similar manners thereto.

Suitable salts of the object compound (I) and the compounds (II) to (IX) are pharmaceutically acceptable conventional non-toxic salts and include a metal salt such as 25 an alkali metal salt (e.g., sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g., trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, etc.), an 30 organic acid salt (e.g., acetate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, trifluoroacetate, etc.), an inorganic acid salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.), a salt with an amino acid (e.g., arginine, aspartic 35 acid, glutamic acid, etc.), or the like.

PGE₂ is known as one of the metabolites in an arachidonate cascade. And it is also known that it has various activities such as pain inducing activity, inflammatory activity, uterine contractile activity, a promoting effect on digestive peristalsis, an awaking activity, a suppressive effect on gastric acid secretion, hypotensive activity, blood platelet inhibition activity, bone-resorbing activity, angiogenic activity, or the like.

PGE₂-sensitive receptors have been sub-divided into four subtypes, EP1, EP2, EP3 and EP4, and these receptors have a wide distribution in various tissues. The effects associated with EP1 and EP3 receptors may be considered as excitatory, and are believed to be mediated by stimulation of phosphatidylinositol turnover or inhibition of adenyl cyclase activity, with resulting decrease in intracellular levels of cyclic AMP. In contrast, the effects associated with EP2 and EP4 receptors may be considered as inhibitory, and are believed to be associated with a stimulation of adenyl cyclase and an increase in levels of intracellular cyclic AMP. Especially, EP4 receptor may be considered to be associated with smooth muscle relaxation, anti-inflammatory or pro-inflammatory activities, lymphocyte differentiation, antiallergic activities, mesangial cell relaxation or proliferation, gastric or enteric mucus secretion, or the like.

The azole compounds represented by the formula (I) or its salts possess binding activities to PGE₂-sensitive receptors, specifically to EP4 receptor, therefore they possess a PGE₂-antagonizing or PGE₂-inhibiting activity.

Therefore, the compounds represented by the formula (I) or its salts are useful for preventing or treating a PGE₂ mediated diseases, especially a EP4 receptors-mediated diseases, such as inflammatory conditions, various pains, or the like in human beings or animals.

More particularly, the compounds represented by formula

(I) and its salt are useful for treating or preventing inflammation and pain in joint and muscle (e.g., rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, juvenile arthritis, etc.), inflammatory skin condition (e.g., sunburn, burns, eczema, dermatitis, etc.), inflammatory eye condition (e.g., conjunctivitis, etc.), lung disorder in which inflammation is involved (e.g., asthma, bronchitis, pigeon fancier's disease, farmer's lung, etc.), condition of the gastrointestinal tract associated with 5 inflammation (e.g., aphthous ulcer, Crohn's disease, atopic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome, etc.), gingivitis, inflammation, pain and tumescence after operation or injury, pyrexia, pain and other conditions 10 associated with inflammation, allergic disease, systemic lupus erythematosus, scleroderma, polymyositis, tendinitis, bursitis, periarthritis nodose, rheumatic fever, Sjögren's syndrome, Behcet disease, thyroiditis, type I diabetes, diabetic complication (diabetic microangiopathy, diabetic 15 retinopathy, diabetic neohropathy, etc.), nephrotic syndrome, aplastic anemia, myasthenia gravis, uveitis contact dermatitis, psoriasis, Kawasaki disease, sarcoidosis, Hodgkin's disease, Alzheimers disease, kidney dysfunction (nephritis, nephritic syndrome, etc), liver dysfunction 20 (hepatitis, cirrhosis, etc.), gastrointestinal dysfunction (diarrhea, inflammatory bowel diseases, etc.) shock, bone disease characterized by abnormal bone metabolism such as osteoporosis (especially, postmenopausal 25 osteoporosis), hyper-calcemia, hyperparathyroidism, Paget's bone diseases, osteolysis, hypercalcemia of malignancy with or without bone metastases, rheumatoid arthritis, periodontitis, osteoarthritis, ostealgia, osteopenia, cancer cachexia, calculosis, lithiasis (especially, urolithiasis), solid carcinoma, or the like in human being or animal.

In order to show the utility of the object compound (I), pharmacological data of the representative compounds thereof are shown in the following.

5 Binding assay using expression of prostanoid receptor subtype

[I] Test Compound :

10 (1) (S)-2-(4,5-Diphenyloxazol-2-yl)-1-(3-methoxybenzyl)-2-cyclopentene

(2) (S)-4-{{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}benzoic acid

15 (3) (S)-{3-{{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}phenoxy}actamide

[II] Test Method :

20 The membrane fraction was prepared using COS-7 cells transfected prostanoid receptor subtype (human EP4).

The Standard assay mixture contained membrane fraction, [³H]-PGE₂ in final volume of 0.25 ml was incubated for 1 hour at 30°C. The reaction was terminated by that the mixture was rapidly filtered through a glass filter (GF/B). Then the filter was washed by 4 ml of ice-cold buffer at two times. The radioactivity associated with the filter was measured by liquid scintillation counting.

30 In the experiment for competition of specific [³H]-PGE₂ was added at a concentration of 10 μM. The following buffer was used in all reactions.

Buffer: 20mM Mes (pH 6.0), 1mM EDTA, 10mM MgCl₂

35 The inhibition (%) of each compound at a concentration of 10μM was shown in Table.

[III] Test Result :

	Test Compound	Inhibition (%)
5	(1) (10 μ M)	>80
	(2) (10 μ M)	>80
	(3) (10 μ M)	>80

Effect on IgE and IgG₁ secretion in mouse B lymphocytes

10

[I] Test Compound

Sodium (S)-3-({2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl}methyl}benzoate

15

[II] Test Method

Inhibitory properties of a test compound against PGE₂-induced IgE and IgG₁ secretion in isolated resting B lymphocytes of mice were tested. Resting mouse B lymphocytes were isolated from spleens of 12-week-old BDF₁ male mice (Clea Japan Inc.) using adherent cell depletion, negative selection by FITC-anti-Thy 1.2 (30H12), FITC-anti-CD4 (GK1.5), FITC-anti-CD11b (M1/70) and FITC-anti-CD8a (5.-6.7) (Pharmingen) with anti-FITC Ab coating magnetic beads (PerSpective Diagnostics) and Percoll gradient (Pharmacia). Resting B lymphocytes were cultured in flat-bottomed 96-well microtiter plates (Becton Dickinson) at 1 x 10⁶ cells per ml and preincubated with a test compound or DMSO control for 30 minutes. Then PGE₂ were added at 10⁻⁶ M. After 1 hour, LPS and IL-4 were added and incubated at 37°C in a humidified atmosphere with 5% CO₂. After 6 days, supernatants were collected and IgE and IgG₁ were measured by the ELISA.

[III] Test Result

	-PGE ₂	+ 10 ⁻⁶ M PGE ₂
IgE secretion (ng/ml)		
Control	27.6 ± 9.9	136.9 ± 22.2 #
+ 10 ⁻⁵ M Test Compound	21.2 ± 5.7	37.0 ± 7.0 *
IgG ₁ secretion (ng./ml)		
Control	680.1 ± 37.9	1970.7 ± 117.5 #
+ 10 ⁻⁵ M Test Compound	1053.0 ± 176.2	1607.6 ± 150.9 #

5

Data : Mean ± S.E.M. (n = 4)

p<0.01 v.s. Control (-PGE₂)* p<0.01 v.s. Control (+ 10⁻⁶ M PGE₂) (Dunett)

10

15

The pharmaceutical composition of the present invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form (e.g., tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, solution, emulsion, suspension etc.), which contains the object compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient, suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation.

20

25

30

35

The pharmaceutical composition of this invention can contain various organic or inorganic carrier materials, which are conventionally used for pharmaceutical purpose, such as excipient (e.g., sucrose, starch, mannit, sorbit, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate, etc.), binding agent (e.g., cellulose, methyl cellulose, hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethyleneglycol, sucrose, starch, etc.), disintegrator (e.g., starch, carboxymethyl cellulose, calcium salt of carboxymethyl cellulose, hydroxypropylstarch,

sodium glycol-starch, sodium bicarbonate, calcium phosphate, calcium citrate, etc.), lubricant (e.g., magnesium stearate, talc, sodium laurylsulfate, etc.), flavoring agent (e.g., citric acid, mentol, glycine, orange powders, etc.),
5 preservative (e.g., sodium benzoate, sodium bisulfite, methylparaben, propylparaben, etc.), stabilizer (e.g., citric acid, sodium citrate, acetic acid, etc.), suspending agent (e.g., methyl cellulose, polyvinylpyrrolidone, aluminum stearate, etc.), dispersing agent, aqueous diluting agent
10 (e.g., water), base wax (e.g., cacao butter, polyethyleneglycol, white petrolatum, etc.).

The effective ingredient may usually be administered with a unit dose of 0.01 mg/kg to 50 mg/kg, 1 to 4 times a day. However, the above dosage may be increased or decreased
15 according to age, weight, conditions of the patient or the administering method.

The patents, patent applications and publications cited
20 herein are incorporated by reference.

Abbreviations used in this application are as follows :

THF	:	Tetrahydrofuran
EtOAc	:	Ethyl acetate
25 Et ₂ O	:	Diethyl ether
DMF	:	N,N-Dimethylformamide
EtOH	:	Ethyl alcohol
MeOH	:	Methyl alcohol
AcOH	:	Acetic acid
30 nBuLi	:	n-Butyllithium
MsCl	:	Methanesulfonyl chloride
pTsOH	:	p-Toluenesulfonic acid
AcONH ₄	:	Ammonium acetate
DMAP	:	Dimethylaminopyridine
35 Pd/C	:	Palladium on carbone

Pd(OH)₂/C : Palladium hydroxide on carbone

The following Preparations and Examples are given only
for the purpose of illustrating the present invention in more
5 detail.

Preparation 1

To a solution of 1-cyclohexene-1-carboxylic acid (100 g) in CH_2Cl_2 (800 ml) was added SOCl_2 (117 ml) at room temperature. After being stirred for 4 hours, the solvent was evaporated in vacuo. The residue was diluted with CH_2Cl_2 (1 l) and benzoin (170 g) and triethylamine (166 ml), and dimethylaminopyridine (10 g) were added to the solution at 0°C under N_2 . After being stirred for 4 hours at room temperature, the solvent was evaporated in vacuo, and the residue was partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat. NaHCO_3 , and brine, dried over MgSO_4 , and evaporated in vacuo. The obtained compound and AcONH_4 (200 g) were dissolved in acetic acid (1500 ml) and the mixture was stirred for 4 hours at 100°C. After the solvent was removed, the residue was partitioned between ethyl acetate and water. The organic layer was washed with water, sat. NaHCO_3 and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give 1-(4,5-diphenyloxazol-2-yl)-1-cyclohexene (171 g).

NMR (CDCl_3 , δ) : 1.6-1.9 (4H, m), 2.2-2.4 (2H, m), 2.5-2.7 (2H, m), 6.90 (1H, m), 7.2-7.8 (10H, m)

Mass (m/z) : 302 ($\text{M}+\text{H}$)⁺

25 Preparation 2

A solution of AD-mix- α ® (30 g) in a mixture of t-BuOH (600 ml) and water (600 ml) was stirred for 1 hour, and then methanesulfonamide (9.3 g) and 1-(4,5-diphenyloxazol-2-yl)-1-cyclohexene added to the solution at room temperature. After being stirred for 20 hours at the same temperature, sodium sulfite (60 g) was added, and the mixture was stirred for 30 minutes. The mixture was partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl solution, sat. NaHCO_3 and brine, dried over MgSO_4 and evaporated in vacuo. The residue was purified by chromatography on silica

gel to afford (1R,2S)-1,2-dihydroxy-1-(4,5-diphenyloxazol-2-yl)cyclohexane (30 g).

IR (neat) : 3400, 3200, 1460 cm⁻¹

NMR (CDCl₃, δ) : 1.2-1.9 (7H, m), 2.2-2.4 (1H, m), 3.34
5 (1H, s), 3.70 (1H, br s), 4.1-4.4 (1H, m), 7.2-7.8
(10H, m)

Mass (m/z) : 365 (M+H)⁺

Preparation 3

10 The following compound was obtained according to a similar manner to that of Preparation 2.

(1) (1S,2R)-1,2-Dihydroxy-1-(4,5-diphenyloxazol-2-yl)-cyclohexane

15 IR (neat) : 3400, 3200, 1460 cm⁻¹

NMR (CDCl₃, δ) : 1.2-1.9 (7H, m), 2.2-2.4 (1H, m), 3.34
5 (1H, s), 3.70 (1H, br s), 4.1-4.4 (1H, m), 7.2-7.8
(10H, m)

Mass (m/z) : 365 (M+H)⁺

20

Preparation 4

To a solution of (1R,2S)-1,2-dihydroxy-1-(4,5-diphenyloxazol-2-yl)cyclohexane (18 g) in CH₂Cl₂ (200 ml) were added orthoacetic acid trimethyl ester (9.7 ml) and

25 p-toluenesulfonic acid (20 mg) at room temperature under N₂.

After being stirred for 30 minutes, the solvent was evaporated in vacuo. The residue was diluted with CH₂Cl₂ (200 ml) and acetyl bromide (5.8 ml) was added to the solution at 0°C under N₂. After being stirred for 2 hours at room

30 temperature, the solvent was evaporated in vacuo, the residue was diluted with MeOH (200 ml), and K₂CO₃ (12 g) was added to the solution at room temperature. The mixture was stirred for 2 hours at the same temperature and partitioned between ethyl acetate and water. The organic layer was washed with 35 1N-HCl, water, sat. NaHCO₃ and brine. The dried solvent was

evaporated in vacuo and the residue was purified by chromatography on silica gel to give (1R,2S)-1-(4,5-diphenyloxazol-2-yl)-1,2-epoxycyclohexane (14.1 g).

5 NMR (CDCl_3 , δ) : 1.2-1.8 (4H, m), 1.9-2.2 (2H, m), 2.2-2.4 (1H, m), 2.6-2.8 (1H, m), 3.83 (1H, m), 7.2-7.6 (10H, m)
Mass (m/z) : 318 ($\text{M}+\text{H}$)⁺

Preparation 5

10 The following compound was obtained according to a similar manner to that of Preparation 4.

(1S,2R)-1-(4,5-Diphenyloxazol-2-yl)-1,2-epoxycyclohexane
NMR (CDCl_3 , δ) : 1.2-1.8 (4H, m), 1.9-2.2 (2H, m), 2.2-2.4 (1H, m), 2.6-2.8 (1H, m), 3.83 (1H, m), 7.2-7.6 (10H, m)
Mass (m/z) : 318 ($\text{M}+\text{H}$)⁺

Preparation 6

20 To a solution of (1R,2S)-1-(4,5-diphenyloxazol-2-yl)-1,2-epoxycyclohexane (20 g) and CuBr (3.0 g) in tetrahydrofuran (400 ml) was dropwise added a solution of 3-methoxybenzylmagnesium chloride [prepared from 3-methoxybenzylchloride (50 g) and Mg (9.2 g)] in tetrahydrofuran (500 ml) at -78°C under N_2 . The mixture was stirred for 2 hours at the room temperature and partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl, water, sat. NaHCO_3 and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give (1R,2S)-1-(4,5-diphenyloxazol-2-yl)-1-hydroxy-2-(3-methoxybenzyl)cyclohexane (29.2 g).

IR (Nujol): 3400, 1600 cm^{-1}
NMR (CDCl_3 , δ) : 1.4-2.4 (9H, m), 3.07 (1H, d, $J=10\text{Hz}$), 3.52 (1H, m), 3.74 (3H, s), 6.7-6.9 (4H, m), 7.15 (1H, t, $J=8\text{Hz}$), 7.2-7.8 (10H, m)

Mass (m/z) : 440 (M+H)⁺

Preparation 7

5 The following compound was obtained according to a similar manner to that of Preparation 6.

(1S,2R)-1-(4,5-Diphenyloxazol-2-yl)-1-hydroxy-2-(3-methoxybenzyl)cyclohexane

10 Preparation 8

To a solution of diisopropylamine (1.44 ml) in THF (8 ml) was added n-BuLi (1.56M solution in hexane, 70 ml) at -60°C. The mixture was warmed to 0°C, stirred for 10 minutes, and recooled to -60°C. To the mixture was added cyclohexanone (0.98 g) in THF (5 ml). After stirring for 1 hour, 3-methoxy-2-methylbenzaldehyde (1.5 g) was added and the mixture was stirred for 1.5 hours at the same temperature. The reaction mixture was quenched with saturated NH₄Cl solution, warmed to room temperature, extracted with EtOAc. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane-EtOAc 4:1 to 2:1) to give 2-[hydroxy-(3-methoxy-2-methylphenyl)methyl]cyclohexanone (1.86 g) as an oil.

25 IR (neat): 3504, 2941, 2862, 1699, 1585, 1468, 1257 cm⁻¹

Mass (m/z) : 231 (H+H-H₂O)⁺

Preparation 9

30 The following compounds described in (1) to (4) were obtained according to a similar manner to that of Preparation 8.

35 (1) 2-[Hydroxy-(3-methoxy-4-methylphenyl)methyl]-cyclohexanone

IR (neat) : 3502, 2939, 2862, 1699, 1612, 1585, 1508,
1466, 1452, 1412, 1255 cm⁻¹
Mass (m/z) : 231 (M+H-H₂O)⁺

5 (2) 2-[Hydroxy-(3-methoxy-5-methylphenyl)methyl]-cyclohexanone

IR (neat) : 3508, 2839, 2862, 1699, 1597, 1464, 1325,
1292 cm⁻¹
Mass (m/z) : 231 (M+H-H₂O)⁺

10

(3) 2-[Hydroxy-(5-methoxy-2-methylphenyl)methyl]-cyclohexanone

IR (neat) : 3508, 2939, 2862, 1697, 1610, 1581, 1500,
1450, 1300, 1248 cm⁻¹

15

Mass (m/z) : 231 (M+H-H₂O)⁺

(4) 2-[Hydroxy-(2-methoxyphenyl)methyl]cyclohexanone

NMR (CDCl₃, δ) : 1.20-2.90 (9H, m), 3.73-3.90 (3H, m),
5.23-5.70 (1H, m), 6.80-7.52 (4H, m)

20

Mass (m/z) : 217 (M+H-H₂O)⁺

Preparation 10

To a solution of 2-[hydroxy-(3-methoxy-2-methylphenyl)-methyl]cyclohexanone (1.85 g) in THF (20 ml) was added conc.

25

HCl (0.5 ml) at 5°C and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with EtOAc, washed with saturated sodium hydrogen carbonate, water, and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was dissolved in MeOH (30 ml) and 10% Pd/C (wet) (400 mg) was added. The mixture was stirred under hydrogen atmosphere at room temperature for 2 hours. The catalyst was removed by filtration and the filtrate was evaporated. The residue was purified by silica gel column chromatography (hexane-EtOAc 12:1 to 8:1) to give 2-(3-methoxy-2-methylbenzyl)cyclohexanone (980.6 mg) as an oil.

35

30

IR (neat) : 2935, 2860, 1709, 1583, 1468, 1257, 1109 cm⁻¹
NMR (CDCl₃, δ) : 1.20-2.58 (10H, m), 2.13 (3H, s), 3.22-
3.34 (1H, m), 3.81 (3H, s), 6.69-6.77 (2H, m), 7.08
(1H, dd, J=7.8, 7.8Hz)

5

Preparation 11

The following compounds described in (1) to (3) were obtained according to a similar manner to that of Preparation 10.

10

(1) 2-(3-Methoxy-4-methylbenzyl)cyclohexanone

IR (neat) : 2937, 2860, 1711, 1612, 1583, 1510, 1450,
1414, 1257 cm⁻¹

NMR (CDCl₃, δ) : 1.23-2.62 (10H, m), 2.17 (3H, s), 3.20
(1H, dd, J=13.5, 4.4Hz), 3.81 (3H, s), 6.60-6.67
(2H, m), 7.02 (1H, d, J=7.4Hz)

15

(2) 2-(3-Methoxy-5-methylbenzyl)cyclohexanone

IR (neat) : 2935, 2860, 1711, 1610, 1595, 1462, 1296,
1151 cm⁻¹

NMR (CDCl₃, δ) : 1.22-2.63 (10H, m), 2.30 (3H, s), 3.18
(1H, dd, J=13.7, 4.4Hz), 3.77 (3H, s), 6.48-6.60
(3H, m)

Mass (m/z) : 233 (M+H)⁺

20

(3) 2-(5-Methoxy-2-methylbenzyl)cyclohexanone

IR (neat) : 2935, 2862, 1709, 1610, 1579, 1502, 1448,
1309, 1288, 1254 cm⁻¹

25

NMR (CDCl₃, δ) : 1.25-2.60 (10H, m), 2.20 (3H, s), 3.22
(1H, dd, J=13.5, 3.8Hz), 3.77 (3H, s), 6.60-6.78
(2H, m), 7.00-7.10 (1H, m)

Preparation 12

A mixture of 2-[hydroxy-(2-methoxyphenyl)methyl]-
35 cyclohexanone (3.71 g), 10% Pd/C (wet) (1.0 g), and 20%

Pd(OH)₂/C (180 mg) in MeOH-EtOAc (2:1, 150 ml) was stirred under hydrogen atmosphere at room temperature for 28 hours. The catalyst was removed by filtration and the filtrate was evaporated. The residue was purified by silica gel column chromatography (hexane-EtOAc 7:1) to give 2-(2-methoxybenzyl)cyclohexanone (2.65 g) as an oil.

5 IR (neat) : 2935, 2860, 1709, 1601, 1587, 1495, 1464,
1244 cm⁻¹
10 NMR (CDCl₃, δ) : 1.22-2.74 (10H, m), 3.22 (1H, dd,
J=13.4, 4.6Hz), 3.79 (3H, s), 6.76-6.92 (2H, m),
7.05-7.23 (2H, m)
Mass (m/z) : 219 (M+H)⁺

Preparation 13

15 To a mixture of (2-oxocyclohex-1-yl)acetic acid (5.6 g), benzoin (7.4 g), 4-dimethylaminopyridine (0.42 g) and dichloromethane (60 ml), 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide hydrochloride (8.7 g) was added in ice-water bath. After the reaction mixture was raised to room
20 temperature, N,N-dimethylformamide (10 ml) was added to dissolve benzoin and stirred overnight. After usual workup, 1,2-diphenyl-2-oxoethyl (2-oxocyclohex-1-yl)acetate (15.5 g) was obtained as a crude solid.

Preparation 14

25 A mixture of ammonium acetate (6.3 g), acetic acid (30 ml) and 1,2-diphenyl-2-oxoethyl (2-oxocyclohex-1-yl)acetate (15.0 g) was heated under reflux for 2.5 hours. After used workup, the crude product was purified by column chromatography (silica gel 100 g, eluent; hexane:ethyl acetate = 20:1 then 9:1 then 6:1) to give 2-[(4,5-diphenyloxazol-2-yl)methyl]cyclohexanone as an amorphous solid.

30 IR (film) : 2935, 1714, 1572, 1502, 1446, 1313, 1220,
1130, 1059, 962, 764, 696 cm⁻¹
35 NMR (CDCl₃, δ) : 1.40-2.06 (4H, m), 2.10-2.57 (4H, m),

2.70 (1H, dd, J=8.2, 15.7Hz), 2.98-3.28 (1H, m),
3.41 (1H, dd, J=7.1, 21.2Hz), 7.30-7.41 (6H, m),
7.55-7.65 (4H, m)

Mass (m/z) : 332 (M+H)⁺, 222

5

Example 1

A mixture of (1R,2S)-1-(4,5-diphenyloxazol-2-yl)-1-hydroxy-2-(3-methoxybenzyl)cyclohexane (28 g) and p-toluene-sulfonic acid (2.5 g) in toluene (300 ml) was stirred for 4 hours under reflux. The solution was washed with water, sat. NaHCO₃ and brine, dried over MgSO₄ and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford (S)-2-(4,5-diphenyloxazol-2-yl)-1-(3-methoxybenzyl)-2-cyclohexene (16 g).

15 NMR (CDCl₃, δ) : 1.4-1.9 (4H, m), 2.1-2.4 (2H, m), 2.53 (1H, dd, J=10.2, 12.8Hz), 3.1-3.3 (1H, m), 3.31 (1H, dd, J=3.2, 12.8Hz), 3.77 (3H, s), 6.80 (1H, 8Hz), 6.9-7.0 (3H, m), 7.20 (1H, t, J=8Hz), 7.2-7.8 (10H, m)

20 Mass (m/z) : 422 (M+H)⁺

Example 2

The following compound was obtained according to a similar manner to that of Example 1.

25

(R)-2-(4,5-Diphenyloxazol-2-yl)-1-(3-methoxybenzyl)-2-cyclohexene

NMR (CDCl₃, δ) : 1.4-1.9 (4H, m), 2.1-2.4 (2H, m), 2.53 (1H, dd, J=10.2, 12.8Hz), 3.1-3.3 (1H, m), 3.31 (1H, dd, J=3.2, 12.8Hz), 3.77 (3H, s), 6.80 (1H, 8Hz), 6.9-7.0 (3H, m), 7.20 (1H, t, J=8Hz), 7.2-7.8 (10H, m)

Mass (m/z) : 422 (M+H)⁺

35

Example 3

To a solution of (S)-2-(4,5-diphenyloxazol-2-yl)-1-(3-methoxybenzyl)-2-cyclohexene (8.5 g) in dichloromethane (100 ml) was added BBr_3 (50 ml, 1M solution in dichloromethane) at 0°C. After being stirred for 2 hours, 5 the solvent was evaporated in vacuo. The residue was diluted with ethyl acetate, and the mixture was washed with water and brine. The dried solvent was evaporated in vacuo and dissolved in dichloromethane (50 ml). To the solution were added trifluoromethanesulfonic acid anhydride (5.0 ml) and 10 2,6-lutidine (6.2 ml) -78°C. After being stirred for 2 hours, the solvent was evaporated in vacuo. The residue was diluted with ethyl acetate, and the mixture was washed with water, sat. NaHCO_3 and brine. The dried solvent was evaporated in vacuo and the residue was purified by 15 chromatography on silica gel to give (S)-3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenyl trifluoromethanesulfonate (9.1 g).

IR (Nujol) : 1600, 1520, 1480 cm^{-1}

20 NMR (CDCl_3 , δ) : 1.4-2.0 (4H, m), 2.2-2.4 (2H, m), 2.60 (1H, dd, $J=10.4, 13.2\text{Hz}$), 3.0-3.2 (1H, m), 3.35 (1H, dd, $J=4.0, 13.2\text{Hz}$), 6.9 (1H, m), 7.1-7.8 (14H, m)

Mass (m/z) : 540 ($\text{M}+\text{H})^+$

25 Example 4

To a dichloromethane solution (30 ml) of 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl]methyl}phenol (3.06 g), triethylamine (1.5 ml) and DMAP (a catalytic amount), was added trifluoroacetic anhydride (1.5 ml) for 5 minutes at -60 30 °C and overnight at room temperature. The solvent was evaporated in vacuo and residue was partitioned between ethyl acetate and 1N hydrochloric acid. The organic layer was washed with brine. After dried over MgSO_4 , the solution was evaporated in vacuo. The residue was purified by silica gel 35 chromatography to afford 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-

cyclopenten-1-yl]methyl}phenyl trifluoromethanesulfonate (3.18 g).

NMR (CDCl_3 , δ) : 1.68-1.92 (1H, m), 2.00-2.20 (1H, m),
5 2.32-2.48 (2H, m), 2.75 (1H, dd, $J=13.5$, 9.0Hz),
3.46 (1H, dd, $J=3.9$, 13.5Hz), 3.54 (1H, m), 6.69
(1H, m), 7.08-7.16 (2H, m), 7.26-7.43 (8H, m),
7.60-7.72 (4H, m)
Mass (m/z) : 526 ($M+H$)⁺

10 Example 5

The following compounds were obtained according to a similar manner to that of Example 3.

15 (1) (R)-3-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}phenyl trifluoromethanesulfonate

(2) (S)-3-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclopenten-1-yl]-methyl}phenyl trifluoromethanesulfonate
IR (Nujol) : 1600, 1580 cm^{-1}
20 NMR (CDCl_3 , δ) : 1.6-2.2 (2H, m), 2.4 (2H, m), 2.75 (1H,
dd, $J=9.0$, 13.4Hz), 3.44 (1H, dd, $J=4.0$, 13.4Hz),
3.56 (1H, m), 6.70 (1H, m), 7.0-7.8 (14H, m)
Mass (m/z) : 526 ($M+H$)⁺

25 Example 6

The following compound was obtained according to a similar manner to that of Example 4.

30 4-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}phenyl trifluoromethanesulfonate
NMR (CDCl_3 , δ) : 1.4-2.0 (4H, m), 2.6-2.8 (1H, m), 3.0-
3.2 (1H, m), 6.86 (1H, m), 7.0-7.5 (14H, m)

Example 7

35 To a solution of (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-

cyclohexen-1-yl]methyl}phenyl trifluoromethanesulfonate (7 g) in a mixture of methanol (30 ml) and dimethylformamide (40 ml) were added 1,3-bis(diphenylphosphino)propane (1.1 mg), palladium acetate (0.58 mg), and triethylamine (5.4 ml).
5 After being stirred for 5 hours at 80°C under CO atmosphere, the mixture was partitioned between ethyl acetate and water and the organic layer was washed with 1N-HCl, sat. NaHCO₃, and brine. The dried solvent was evaporated in vacuo and the obtained solid was washed with ether to afford methyl (S)-3-
10 {[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-benzoate (4.2 g).

IR (Nujol): 1720 cm⁻¹

NMR (CDCl₃, δ) : 1.4-2.0 (4H, m), 2.1-2.4 (2H, m), 2.62
15 (1H, dd, J=10.0, 13.0Hz), 3.16 (1H, m), 3.33 (1H,
dd, J=3.0, 13.0Hz), 3.88 (3H, s), 6.92 (1H, t,
J=4.0Hz), 7.3-7.8 (12H, m), 7.85 (1H, d, J=8Hz),
8.00 (1H, s)

Mass (m/z) : 450 (M+H)⁺

20 Example 8

The following compounds were obtained according to a similar manner to that of Example 7.

(1) Methyl (R)-3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl)methyl}benzoate
25 IR (Nujol): 1720 cm⁻¹
NMR (CDCl₃, δ) : 1.4-2.0 (4H, m), 2.1-2.4 (2H, m), 2.62
30 (1H, dd, J=10.0, 13.0Hz), 3.16 (1H, m), 3.33 (1H,
dd, J=3.0, 13.0Hz), 3.88 (3H, s), 6.92 (1H, t,
J=4.0Hz), 7.3-7.8 (12H, m), 7.85 (1H, d, J=8Hz),
8.00 (1H, s)
Mass (m/z) : 450 (M+H)⁺

(2) Methyl 4-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl)methyl}benzoate
35

IR (Nujol) : 1720 cm⁻¹
NMR (CDCl₃, δ) : 1.4-2.0 (4H, m), 2.2-2.4 (2H, m), 2.63
5 (1H, dd, J=10.2, 13.0Hz), 3.20 (1H, m), 3.39 (1H,
dd, J=3.4, 13.0Hz), 3.89 (3H, s), 6.92 (1H, m),
7.2-7.8 (12H, m), 7.96 (2H, d, J=8Hz)
Mass (m/z) : 450 (M+H)⁺

(3) Ethyl (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl]methyl}benzoate
10 IR (Nujol) : 1720 cm⁻¹
Mass (m/z) : 450 (M+H)⁺

Example 9

To a solution of methyl (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoate (0.3 g) in a mixture of ethanol (8 ml) and tetrahydrofuran (5 ml) was added 1N-NaOH solution (3.5 ml). After being stirred for 24 hours at the same temperature, the solvent was removed. The residue was partitioned between ethyl acetate and 1N-HCl and the organic layer was washed with brine. The dried solvent was evaporated in vacuo and the obtained solid was washed with a mixture hexane and ether to afford (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid(0.28 g).

25 IR (Nujol) : 1700 cm⁻¹
NMR (CDCl₃, δ) : 1.4-1.9 (4H, m), 2.2-2.4 (2H, m), 2.65
(1H, dd, J=10.0, 13.0Hz), 3.2 (1H, m), 3.35 (1H,
dd, J=3.0, 13.0Hz), 6.93 (1H, t, J=3.8Hz), 7.2-7.8
(12H, m), 7.93 (1H, d, J=8Hz), 8.10 (1H, s)
Mass (m/z) : 436 (M+H)⁺

30

Example 10

The following compounds were obtained according to a similar manner to that of Example 9.

35 (1) (R)-3-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-

methyl}benzoic acid

IR (Nujol) : 1700 cm⁻¹

NMR (CDCl₃, δ) : 1.4-1.9 (4H, m), 2.2-2.4 (2H, m), 2.65
 5 (1H, dd, J=10.0, 13.0Hz), 3.2 (1H, m), 3.35 (1H,

dd, J=3.0, 13.0Hz), 6.93 (1H, t, J=3.8Hz), 7.2-7.8
 (12H, m), 7.93 (1H, d, J=8Hz), 8.10 (1H, s)

Mass (m/z) : 436 (M+H)⁺

(2) 4-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-

10 methyl}benzoic acid

IR (Nujol) : 1690 cm⁻¹

NMR (CDCl₃, δ) : 1.4-1.9 (4H, m), 2.2-2.4 (2H, m), 2.6-
 15 2.8 (1H, m), 3.2 (1H, m), 3.40 (1H, dd, J=3.2,
 13.2Hz), 6.93 (1H, m), 7.2-7.8 (12H, m), 8.03 (2H,

d, J=8Hz)

Mass (m/z) : 436 (M+H)⁺

(3) (S)-3-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclopenten-1-

yl]methyl}benzoic acid

20 IR (Nujol) : 1680 cm⁻¹

NMR (CDCl₃) : 1.7-1.9 (1H, m), 2.0-2.2 (1H, m), 2.38-
 2.52 (2H, m), 2.74 (1H, dd, J=12.7, 9.1Hz), 3.46
 (1H, dd, J=12.7, 4.2Hz), 3.60 (1H, m), 6.72 (1H,
 m), 7.2-7.7 (12H, m), 7.9-8.0 (2H, m).

25 Mass (m/z) : 422 (M+H)⁺

(4) 3-{[(1S,2S)-2-(4,5-Diphenyloxazol-2-yl)-1-cyclopentyl]-

methyl}benzoic acid

IR (Nujol) : 1680 cm⁻¹

30 NMR (CDCl₃, δ) : 1.4-2.4 (6H, m), 2.4-2.8 (3H, m), 3.52
 (1H, m), 7.2-7.4 (8H, m), 7.5-7.7 (4H, m), 7.8-8.0
 (2H, m)

Mass (m/z) : 424 (M+H)⁺

35 (5) 3-{[(1S,2R)-2-(4,5-Diphenyloxazol-2-yl)-1-cyclopentyl]-

methyl}benzoic acid
Mass (m/z) : 424 (M+H)⁺
IR (Nujol) : 1680 cm⁻¹
NMR (CDCl₃, δ) : 1.4-2.5 (6H, m), 2.5-3.1 (4H, m), 7.2-
5 7.8 (12H, m), 7.82 (1H, d, J=8Hz), 7.93 (1H, s)

(6) 3-{[2-(4,5-Diphenyloxazol-2-yl)-1-cyclopenten-1-yl]-
methyl}benzoic acid
IR (Nujol) : 1680 cm⁻¹
10 NMR (CDCl₃, δ) : 1.7-2.0 (2H, m), 2.4-2.6 (2H, m), 2.9-
3.1 (2H, m), 4.21 (2H, s), 7.2-7.7 (10H, m), 7.9-
8.1 (4H, m)
Mass (m/z) : 422 (M+H)⁺

15 Example 11

A mixture of (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (0.1 g) and 10% Pd/C (0.1 g) in methanol (20 ml) was stirred under H₂ for 8 hours. The catalyst was filtered off and filtrate was evaporated in vacuo to give 3-{[(1S)-2-(4,5-diphenyloxazol-2-yl)-1-cyclohexyl]methyl}benzoic acid (0.1 g).

20 IR (neat) : 3400, 1690 cm⁻¹
NMR (CDCl₃, δ) : 1.2-2.5 (9H, m), 2.6-3.0 (2H, m), 3.25
~ (1H, m), 7.2-8.1 (14H, m)
25 Mass (m/z) : 438 (M+H)⁺

Example 12

The following compounds were obtained from ethyl (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl]-
30 methyl}benzoate according to a similar manner to that of Example 11.

(1) Ethyl 3-{[(1S,2S)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzoate

(2) Ethyl 3-{{(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl}methyl}benzoate

Example 13

To a solution of (S)-3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (0.3 g) in a tetrahydrofuran (10 ml) were added isobutyl chloroformate (0.15 ml) and triethylamine (0.2 ml) at 0°C under N₂. After being stirred for 30 minutes, NH₃ (5 ml, 4M solution in methanol) was added to the mixture. After being stirred for 30 minutes, the solvent was removed in vacuo. The residue was partitioned between ethyl acetate and 1N-NaOH and the organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel to give and the obtained residue was purified by chromatography on silica gel to give (S)-3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-benzamide (0.03 g).

IR (Nujol) : 1660 cm⁻¹

NMR (CDCl₃, δ) : 1.4-1.0 (4H, m), 2.2-2.4 (2H, m), 2.65 (1H, dd, J=9.8, 13.0Hz), 3.15 (1H, m), 3.20 (1H, dd, J=4.0, 13.0Hz), 5.5 (1H, br s), 6.1 (1H, br s), 6.92 (1H, m), 7.2-7.9 (13H, m)

Mass (m/z) : 435 (M+H)⁺

25

Example 14

The following compounds were obtained according to a similar manner to that of Example 13.

30 (1) 3-{{(1S,2S)-2-(4,5-Diphenyloxazol-2-yl)-1-cyclopentyl}-methyl}benzamide
IR (Nujol) : 1650 cm⁻¹
NMR (CDCl₃, δ) : 1.5-2.4 (6H, m), 2.4-2.8 (3H, m), 3.48 (1H, m), 5.6 (1H, br s), 6.09 (1H, br s), 7.2-7.7 (14H, m)

35

Mass (m/z) : 423 (M+H)⁺

(2) 3-{[(1S,2R)-2-(4,5-Diphenyloxazol-2-yl)-1-cyclopentyl]-
5 methyl}benzamide

IR (Nujol) : 1650 cm⁻¹

NMR (CDCl₃, δ) : 1.4-2.5 (6H, m), 2.6-3.0 (4H, m), 5.4
(1H, br s), 6.0 (1H, br s), 7.2-7.7 (14H, m)

Mass (m/z) : 423 (M+H)⁺

10 (3) 3-{[2-(4,5-Diphenyloxazol-2-yl)-1-cyclopenten-1-yl]-
methyl}benzamide

IR (Nujol) : 1660 cm⁻¹

NMR (CDCl₃, δ) : 1.8-2.0 (2H, m), 2.4-2.6 (2H, m), 2.9-
3.1 (2H, m), 4.19 (2H, s), 4.67 (1H, br s), 5.96
(1H, br s), 7.2-7.8 (14H, m)

15 Mass (m/z) : 421 (M+H)⁺

Example 15

To a solution of (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (3 g) in a methanol (30 ml) was added 1N-NaOH solution (6.9 ml). After being stirred for 5 minutes, the solvent was removed in vacuo to give sodium (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoate (3 g).

25 NMR (DMSO-d₆) : 1.4-2.0 (4H, m), 2.2-2.4 (2H, m), 3.0-
3.1 (1H, m), 6.91 (1H, m), 7.0-7.8 (12H, m), 7.83
(1H, s)

Example 16

30 To a solution of (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (0.2 g) in a tetrahydrofuran (10 ml) were added isobutyl chloroformate (0.15 ml) and triethylamine (0.2 ml) at 0°C under N₂. After being stirred for 30 minutes, NH₃ (5 ml, 4M solution in
35 methanol) was added to the mixture. After being stirred for

30 minutes, the solvent was removed in vacuo. The residue was partitioned between ethyl acetate and 1N-NaOH and the organic layer was washed with brine. The dried solvent was evaporated in vacuo. The residue and 10 % Pd/C (0.2 g) in 5 methanol (20 ml) was stirred under H₂ for 8 hours. The catalyst was filtered off and filtrate was evaporated in vacuo. The residue was purified by chromatography on silica gel to give and the obtained residue was purified by chromatography on silica gel to give 3-{{(1S)-2-(4,5-diphenyloxazol-2-yl)-1-cyclohexyl}methyl}benzamide (0.11 g).
10

IR (neat) : 3300, 3200, 1660 cm⁻¹
NMR (CDCl₃, δ) : 1.2-2.4 (9H, m), 2.5-2.8 (2H, m), 3.2 (1H, m), 5.5 (1H, br s), 6.0 (1H, br s), 7.2-7.8 (14H, m)
15 Mass (m/z) : 437 (M+H)⁺

Example 17

A dimethylformamide (8 ml) - MeOH (4 ml) solution of 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl]methyl}-phenyl trifluoromethanesulfonate (2.24 g), Palladium(II) acetate (64 mg), 1,3-bis(diphenylphosphino)propane (106 mg) and triethylamine (1.2 ml) was saturated with CO gas. The solution was stirred for 14 hours at 70°C under CO atmosphere. The solvent was evaporated in vacuo and the residue was partitioned between ethyl acetate and water. The organic layer was washed with 1N hydrochloric acid, water and brine. After dried over MgSO₄, the organic solvent was evaporated in vacuo. The residue was purified by silica gel chromatography to afford methyl 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl]methyl}benzoate (1.17 g).
20
25
30

IR (neat) : 1710, 1630 cm⁻¹
NMR (CDCl₃, δ) : 1.65-1.97 (1H, m), 1.97-2.19 (1H, m), 2.39-2.50 (2H, m), 2.71 (1H, dd, J=13.4, 9.2Hz), 3.46 (1H, dd, J=13.4, 4.1Hz), 3.78 (1H, m), 3.88 (3H, s), 6.70 (1H, m), 7.29-7.46 (8H, m), 7.59-7.72
35

(4H, m), 7.83-7.93 (2H, m)

Example 18

To a methanol solution (7 ml) of methyl 3-[(2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl)methyl]benzoate (1.15 g) was added 1N aqueous sodium hydroxide solution (4 ml). The solution was stirred overnight at room temperature. The solvent was evaporated in vacuo and the residue was partitioned between ethyl acetate and 1N hydrochloric acid. The organic layer was washed with brine. After dried over MgSO₄, the organic solvent was evaporated in vacuo to afford 3-[(2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl)methyl]benzoic acid (1.02 g).

IR (Nujol) : 1680 cm⁻¹
NMR (CDCl₃, δ) : 1.72-1.92 (1H, m), 2.00-2.20 (1H, m), 2.38-2.52 (2H, m), 2.74 (1H, dd, J=12.7, 9.1Hz), 3.46 (1H, dd, J=12.7, 4.2Hz), 3.60 (1H, m), 6.72 (1H, m), 7.26-7.72 (12H, m), 7.90-8.01 (2H, m)
Mass (m/z) : 422 (M+H)⁺

20

Example 19

To a tetrahydrofuran solution (10 ml) of 3-[(2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl)methyl]benzoic acid (0.30 g) and triethylamine (0.15 ml) was added ethyl chloroformate (0.15 ml) at 0°C. The solution was stirred for 30 minutes at the same temperature. Then aqueous ammonia (10 ml) was added to the solution. After stirred for 6 hours at 0°C, the solution was partitioned between ethyl acetate and water. The organic layer was washed with water, 1N hydrochloric acid, water and brine. After dried over MgSO₄, the solvent was evaporated in vacuo to afford 3-[(2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl)methyl]benzamide (0.24 g).

IR (Nujol) : 3800, 3160, 1640, 1620 cm⁻¹
NMR (CDCl₃, δ) : 1.72-2.20 (2H, m), 2.38-2.54 (2H, m),

2.72 (1H, dd, J=13.5, 9.1Hz), 3.43 (1H, dd, J=13.5, 4.0Hz), 3.60 (1H, m), 6.71 (1H, m), 7.34-7.52 (9H, m), 7.57-7.70 (7H, m)

Mass (m/z) : 421 (M+H)⁺, 403 (M-NH₃)⁺

5

Example 20

3-{{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclopenten-1-yl]-methyl}benzamide (75 mg) was hydrogenated over 5% Pd/C (3 mg) in methanol (20 ml) at room temperature at 3 atm for 7 hours.

10 The mixture was filtered and the filtrate was evaporated in vacuo. The residue was triturated with a mixture of ether and n-hexane to afford 3-{{[2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide (54 mg).

IR (KBr) : 3334, 3199, 3059, 2954, 2869, 1662 cm⁻¹

15 NMR (DMSO-d₆, δ) : 1.20-3.12 (9H, m), 3.48 (1H, m), 7.15-8.00 (16H, m)

Mass (m/z) : 423 (M+H)⁺, 405 (M-NH₃)⁺

Example 21

20 To a solution of ethyl (S)-{3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenoxy}acetate (0.5 g) in tetrahydrofuran (5 ml) was added NH₃ (5 ml, 4N methanol solution). After being stirred for 24 hours, the solvent was removed. The residue was purified by chromatography on silica gel to give (S)-{3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenoxy}acetamide (220 mg).

IR (Nujol) : 1640 cm⁻¹

NMR (CDCl₃, δ) : 1.4-2.0 (4H, m), 2.2-2.4 (2H, m), 2.56 (1H, dd, J=9.8, 12.8Hz), 3.20 (1H, m), 3.32

30 (1H, dd, J=4.0, 12.8Hz), 4.46 (2H, s), 5.8 (1H, br s), 6.5 (1H, br s), 6.8-7.8 (14H, m)

Mass (m/z) : 465 (M+H)⁺

Example 22

35

To a solution of 2-(4,5-diphenyloxazol-2-yl)-3-(3-methoxybenzyl)bicyclo[2.2.1]hept-2-ene (3.4 g) in dichloromethane (35 ml) was added BBr_3 (17 ml, 1M solution in dichloromethane) at 0°C. After being stirred for 2 hours, 5 the solvent was evaporated in vacuo. The residue was diluted with ethyl acetate, and the mixture was washed with water and brine. The dried solvent was evaporated in vacuo and dissolved in dichloromethane (20 ml). To the solution were added trifluoromethanesulfonic anhydride (0.8 ml) and 2,6-lutidine (1.1 ml) -78°C. After being stirred for 2 hours, 10 the solvent was evaporated in vacuo. The residue was diluted with ethyl acetate, and the mixture was washed with water, sat. NaHCO_3 and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on 15 silica gel to give a Tf-compound [3-{[3-(4,5-diphenyloxazol-2-yl)bicyclo[2.2.1]hept-2-en-2-yl]methyl}phenyl trifluoromethansulfonate] (1.6 g).

To a solution of the Tf-compound (1.6 g) in a mixture of methanol (10 ml) and DMF (20 ml) were added 1,3-bis(diphenylphosphino)propane (480 mg), palladium acetate (260 mg), and triethylamine (1.2 ml). After being stirred for 5 hours at 80°C under carbone monooxide atmosphere, the mixture was partitioned between ethyl acetate and water and the organic layer was washed with 1N-HCl, sat. NaHCO_3 , and brine. The dried solvent was evaporated in vacuo and the obtained solid was washed with ether to afford methyl 3-{[3-(4,5-diphenyloxazol-2-yl)bicyclo[2.2.1]hept-2-en-2-yl]- 20 methyl}benzoate (1.0 g).

IR (Nujol) : 1720 cm^{-1}
30 NMR (CDCl_3 , δ) : 1.0-2.0 (6H, m), 2.85 (1H, br s), 3.62 (1H, br s), 3.86 (1H, d, $J=14\text{Hz}$), 3.89 (3H, s), 4.40 (1H, d, $J=14\text{Hz}$), 7.2-8.0 (14H, m)
Mass (m/z) : 462 ($\text{M}+\text{H}$)⁺

The following compound was obtained according to a similar manner to that of Example 22.

5 Methyl 3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohepten-1-
yl}methyl}benzoate

IR (Nujol) : 1720 cm⁻¹

10 NMR (CDCl₃, δ) : 1.4-2.0 (6H, m), 2.4-2.6 (2H, m), 2.91
(1H, dd, J=10.0, 14.0Hz), 3.09 (1H, dd, J=6.6,
14Hz), 3.81 (3H, s), 7.08 (1H, t, J=8.0Hz), 7.2-7.8
(12H, m), 7.80 (1H, d, J=8Hz), 8.00 (1H, s)

Mass (m/z) : 464 (M+H)⁺

Example 24

15 To a solution of methyl 3-{{3-(4,5-diphenyloxazol-2-
yl)bicyclo[2.2.1]hept-2-en-2-yl}methyl}benzoate (1.0 g) in a
mixture of methanol (10 ml) and THF (10 ml) was added 1N-NaOH
solution (11 ml). After being stirred for 5 minutes, the
solvent was removed in vacuo. The residue was dissolved in a
mixture of ethyl acetate and 1N-HCl solution. The organic
20 layer was washed with brine and dried over MgSO₄. The
solution was evaporated in vacuo to give 3-{{3-(4,5-
diphenyloxazol-2-yl)bicyclo[2.2.1]hept-2-en-2-yl}methyl}-
benzoic acid (1.0 g).

IR (Nujol) : 1690 cm⁻¹

25 NMR (CDCl₃, δ) : 1.0-2.0 (6H, m), 2.86 (1H, br s), 3.68
(1H, br s), 3.86 (1H, d, J=15Hz), 4.39 (1H, d,
J=14Hz), 7.2-8.2 (14H, m)

Mass (m/z) : 448 (M+H)⁺

30 Example 25

The following compounds described in (1) to (3) were obtained in a similar manner to that of Example 24.

35 (1) 3-{{2-(4,5-Diphenyloxazol-2-yl)-2-cyclohepten-1-yl}-
methyl}benzoic acid

IR (Nujol) : 1690 cm⁻¹
NMR (CDCl₃, δ) : 1.4-2.0 (6H, m), 2.4-2.6 (2H, m), 2.94
5 (1H, dd, J=10.0, 14.0Hz), 3.12 (1H, dd, J=10,
14Hz), 4.11 (1H, m), 7.11 (1H, t, J=8.0Hz), 7.2-7.8
(12H, m), 7.89 (1H, d, J=8Hz), 8.10 (1H, s)
Mass (m/z) : 450 (M+H)⁺

- (2) (S)-3-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-
10 methyl}phenylacetic acid
NMR (CDCl₃, δ) : 1.4-1.8 (4H, m), 2.1-2.4 (2H, m), 2.5-
2.8 (1H, m), 3.1-3.4 (2H, m), 6.93 (1H, m), 7.0-8.2
(14H, m)
Mass (m/z) : 450 (M+H)⁺
- 15 (3) 3-{3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-
methyl}phenyl}propionic acid sodium salt
IR (Nujol) : 1580 cm⁻¹
NMR (DMSO-d₆, δ) : 1.4-2.0 (4H, m), 2.1-2.5 (5H, m),
2.6-2.9 (2H, m), 2.9-3.2 (2H, m), 6.8-7.2 (4H, m),
20 7.2-7.8 (10H, m)
Mass (m/z) : 464 (M+H-Na)⁺

Example 26

To a solution of 3-{[3-(4,5-diphenyloxazol-2-yl)-
25 bicyclo[2.2.1]hept-2-en-2-yl]methyl}benzoic acid (0.46 g) in
a THF (10 ml) were added isobutyl chloroformate (0.26 ml) and
triethylamine (0.3 ml) at 0°C under N₂. After being stirred
for 30 minutes, NH₃ (5 ml, 4M solution in methanol) was added
to the mixture. After being stirred for 30 minutes, the
30 solvent was removed in vacuo. The residue was partitioned
between ethyl acetate and 1N-NaOH and the organic layer was
washed with brine. The dried solvent was evaporated in vacuo
to give 3-{[3-(4,5-diphenyloxazol-2-yl)bicyclo[2.2.1]hept-2-
en-2-yl]methyl}benzamide (0.2 g).

35 IR (neat) : 3350, 3150, 1660 cm⁻¹

NMR (CDCl_3 , δ) : 1.2-2.4 (6H, m), 2.86 (1H, br s), 3.61 (1H, br s), 3.82 (1H, d, $J=14\text{Hz}$), 4.40 (1H, d, $J=14\text{Hz}$), 7.2-7.8 (14H, m)
Mass (m/z) : 447 ($\text{M}+\text{H}$)⁺

5

Example 27

The following compound was obtained in a similar manner to that of Example 26.

10 3-({[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohepten-1-yl]methyl}-benzamide
1}-benzamide
IR (neat) : 3350, 3150, 1660 cm^{-1}
NMR (CDCl_3 , δ) : 1.4-2.0 (6H, m), 2.42 (2H, m), 2.91 (1H, dd, $J=8.6$, 13.4Hz), 3.10 (1H, dd, $J=7.2$, 13.4Hz), 3.78 (1H, m), 7.09 (1H, t, $J=8\text{Hz}$), 7.2-7.8 (14H, m)
15
Mass (m/z) : 449 ($\text{M}+\text{H}$)⁺

Example 28

20 A solution of (S)-3-({[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (0.5 g), diphenylphosphoryl azide (0.30 ml), and triethylamine (0.2 ml) in toluene (20 ml) was stirred for 1 hour under reflux. To the mixture was added benzylalcohol and stirred for 15 hours under reflux. The cooled solvent was evaporated in vacuo and the obtained residue was purified by chromatography on silica gel to afford benzyl (S)-3-({[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenylcarbamate (0.4 g).

25 IR (Nujol) : 1720 cm^{-1}
30 NMR (CDCl_3 , δ) : 1.4-1.8 (4H, m), 2.3 (1H, m), 2.53 (1H, dd, $J=9.6$, 12Hz), 3.20 (1H, m), 3.28 (1H, dd, $J=4.0$, 12Hz), 5.19 (2H, s), 6.60 (1H, s), 6.86 (1H, m), 7.03 (1H, d, $J=8\text{Hz}$), 7.2-7.8 (13H, m)
Mass (m/z) : 541 ($\text{M}+\text{H}$)⁺

Example 29

A mixture of 3-{[3-(4,5-diphenyloxazol-2-yl)bicyclo-[2.2.1]hept-2-en-2-yl]methyl}benzoic acid (0.3 g) and 10% Pd/C (0.1 g) in methanol (20 ml) was stirred under H₂ for 8 hours. The catalyst was filtered off and filtrate was evaporated in vacuo to give 3-{[3-(4,5-diphenyloxazol-2-yl)bicyclo[2.2.1]hept-2-yl]methyl}benzoic acid (0.27 g).

IR (Nujol) : 1690 cm⁻¹

NMR (CDCl₃, δ) : 1.2-2.8 (11H, m), 3.60 (1H, m), 7.2-8.0 (14H, m)

Mass (m/z) : 450 (M+H)⁺

Example 30

The following compounds described in (1) to (4) were obtained in a similar manner to that of Example 29.

(1) 3-{[3-(4,5-Diphenyloxazol-2-yl)bicyclo[2.2.1]hept-2-yl]methyl}benzamide

IR (Nujol) : 1660 cm⁻¹

NMR (CDCl₃, δ) : 1.2-2.8 (11H, m), 3.52 (1H, m), 7.2-7.8 (14H, m)

Mass (m/z) : 449 (M+H)⁺

(2) 3-{[2-(4,5-Diphenyloxazol-2-yl)-1-cycloheptyl]methyl}-benzoic acid

IR (Nujol) : 1690 cm⁻¹

NMR (CDCl₃, δ) : 1.2-2.2 (10H, m), 2.5-3.0 (3H, m), 3.34 (1H, m), 7.2-6.0 (12H, m), 7.8-8.0 (2H, m)

Mass (m/z) : 452 (M+H)⁺

(3) 3-{[2-(4,5-Diphenyloxazol-1-yl)-1-cycloheptyl]methyl}-benzamide

IR (Nujol) : 1640 cm⁻¹

NMR (CDCl₃, δ) : 1.3-2.2 (10H, m), 2.4-3.0 (3H, m), 3.28 (1H, m), 7.2-7.8 (10H, m)

Mass (m/z) : 451 (M+H)⁺

(4) (S)-3-{[2-(4,5-Diphenyloxazol-2-yl)-1-cyclohexyl]-
methyl}aniline

5 IR (Nujol) : 1600 cm⁻¹

NMR (CDCl₃, δ) : 1.4-2.8 (11H, m), 3.22 (1H, m), 6.4-6.6
(2H, m), 7.0-7.8 (12H, m)

Mass (m/z) : 409 (M+H)⁺

10 Example 31

To a solution of (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-1-cyclohexyl]methyl}aniline (70 mg) in dichloromethane (10 ml) were added pyridine (1 ml) and MsCl (0.032 ml). After stirred for 2 hours at the room temperature, the mixture was partitioned between ethyl acetate and water and the organic layer was washed with 1N-HCl, sat. NaHCO₃, and brine. The dried solvent was evaporated in vacuo and the obtained solid was washed with ether to afford (S)-N-{3-{[2-(4,5-diphenyloxazol-2-yl)-1-cyclohexyl]methyl}phenyl}-
20 methanesulfonamide (0.05 g).

IR (Nujol) : 1600 cm⁻¹

NMR (CDCl₃, δ) : 1.2-2.8 (11H, m), 2.87 (3H, s), 3.2
(1H, m), 6.37 (1H, m), 6.9-7.8 (14H, m)

Mass (m/z) : 487 (M+H)⁺

25

Example 32

To a solution 4,5-diphenyloxazole (1.2 g) in THF (20 ml) was added n-BuLi (3.7 ml, 1.6M solution in hexane) at -78°C. After stirred for 30 minutes at the same temperature, a solution of 2-(3-cyanobenzyl)hexanone (1.0 g) in THF (10 ml) was added to the mixture. After stirred for 2 hours at the same temperature, the mixture was partitioned between ethyl acetate and water. The organic layer was washed with 1N-HCl, water, sat. NaHCO₃ and brine. The dried solvent was evaporated in vacuo and the residue was purified by
30
35

chromatography on silica gel to give alcohol compound. A mixture of the alcohol compound and p-toluenesulfonic acid (0.01 g) in toluene (30 ml) was stirred for 7 hours under reflux. The solution was washed with water, sat. NaHCO₃, and brine, dried over MgSO₄, and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}benzonitrile (0.86 g).

IR (Nujol) : 2200 cm⁻¹

NMR (CDCl₃, δ) : 1.4-1.9 (4H, m), 2.2-2.4 (2H, m), 2.59 (1H, dd, J=10.0, 13.2Hz), 3.1-3.3 (1H, m), 3.33 (1H, dd, J=3.4, 13.2Hz), 6.92 (1H, d, J=3.8Hz), 7.2-7.8 (14H, m)

Mass (m/z) : 417 (M+H)⁺

Example 33

The following compound was obtained in a similar manner to that of Example 32.

Ethyl 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenyl}propionate

IR (Nujol) : 1730 cm⁻¹

NMR (CDCl₃, δ) : 1.22 (3H, t, J=8Hz), 1.4-2.0 (4H, m), 2.2-2.4 (2H, m), 2.5-2.8 (3H, m), 2.8-3.0 (2H, m), 3.1-3.3 (2H, m), 4.17 (2H, q, J=8Hz), 6.8-7.1 (2H, m), 7.1-7.8 (13H, m)

Mass (m/z) : 492 (M+H)⁺

Example 34

To a solution of (S)-3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenyl trifluoromethanesulfonate (1.17 g) in dichloromethane (100 ml) were added 5-(2-boronophenyl)-2-(triphenylmethyl)-2H-tetrazole (1.16 g), tetrakis(triphenylphosphine)palladium (600 mg), and K₂CO₃ (630 mg) in a mixture of DMF and water. After being stirred

for 8 hours at 100°C, the solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel to give (S)-2-(4,5-diphenyloxazol-2-yl)-1-{3-[2-(triphenylmethyl)tetrazol-5-yl]phenyl}benzyl}-2-cyclohexene (0.83 g).

5 IR (Nujol) : 1600 cm⁻¹
NMR (CDCl₃, δ) : 1.4-1.8 (4H, m), 2.2-2.4 (3H, m), 3.0-3.2 (2H, m), 6.8-7.0 (6H, m), 7.0-8.0 (27H, m)

Example 35

10 To a solution of (S)-2-(4,5-diphenyloxazol-2-yl)-1-{3-[2-(triphenylmethyl)tetrazol-5-yl]phenyl}benzyl}-2-cyclohexene (0.8 g) in methanol (20 ml) was added conc. HCl solution (2 ml). After being stirred for 4 hours, the solvent was evaporated in vacuo. The residue was purified by 15 chromatography on silica gel to give (S)-2-(4,5-diphenyloxazol-2-yl)-1-{3-[2-(tetrazol-5-yl)phenyl]benzyl}-2-cyclohexene (50 mg).

15 IR (Nujol) : 1600 cm⁻¹
NMR (CDCl₃, δ) : 1.2-1.8 (4H, m), 2.2-2.4 (2H, m), 2.6-3.2 (3H, m), 6.8-7.6 (19H, m), 8.03 (1H, d, J=8Hz)
20 Mass (m/z) : 536 (M+H)⁺

Example 36

25 To a solution of 2-(4,5-diphenyloxazol-2-yl)-1-(3-cyanobenzyl)-2-cyclohexene (400 mg) in DMF (8 ml) were added NaN₃ (100 mg) and NH₄Cl (80 mg). After stirred for 12 hours at 120°C, the mixture was partitioned between ethyl acetate and water and the organic layer was washed with 1N-HCl and brine. The dried solvent was evaporated in vacuo and the 30 obtained solid was washed with a mixture of ether and n-hexane to afford 2-(4,5-diphenyloxazol-2-yl)-1-{3-(1H-tetrazol-5-yl)benzyl}-2-cyclohexene (0.36 g).

35 NMR (CDCl₃, δ) : 1.3-2.0 (4H, m), 2.2-2.5 (2H, m), 2.66 (1H, dd, J=10, 14Hz), 3.1-3.3 (2H, m), 6.91 (1H, t, J=4.2Hz), 7.1-7.8 (12H, m), 7.8-8.0 (2H, m)

Mass (m/z) : 460 (M+H)⁺

Example 37

To a solution of (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (0.2 g) in CH₂Cl₂ (10 ml) was added SOCl₂ (1 ml) and stirred for 1 hour at the room temperature. After the solvent was evaporated in vacuo, the residue was dissolved in a mixture of THF and CH₃CN. To the solution were added (trimethylsilyl)diazomethane (0.34 ml) and triethylamine (0.1 ml) at 0°C. After stirred for 48 hours at the same temperature, the solvent was evaporated in vacuo, and benzylalcohol (1.8 ml) and 2,4,6-collidine (1.8 ml) were added to there. After stirred for 20 minutes at 180°C, the mixture was diluted with toluene and purified by chromatography on silica gel to afford benzyl (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenylacetate (0.14 g).

IR (Nujol) : 1720 cm⁻¹

NMR (CDCl₃, δ) : 1.4-1.8 (4H, m), 2.3-2.5 (2H, m), 2.4-2.6 (1H, m), 3.0-3.4 (2H, m), 6.92 (1H, m), 7.0-8.0 (19H, m)

Mass (m/z) : 540 (M+H)⁺

Example 38

To a solution of 4,5-diphenyloxazole (990 mg) in THF (15 ml) was added n-BuLi (1.56M solution in hexane, 2.87 ml) at -60°C and stirred for 1 hour. To the mixture was added a solution of 2-(3-methoxy-2-methylbenzyl)cyclohexanone (945 mg) in THF (4 ml), warmed to 5°C, and stirred for 2 hours. To the reaction mixture was added 1N HCl and extracted with EtOAc. The organic layer was washed with water, saturated sodium hydrogen carbonate, water, and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was dissolved in toluene (45 ml) and p-TsOH·H₂O (79 mg) was added. The mixture was refluxed for 48 hours, cooled to room

temperature, diluted with EtOAc, washed with saturated sodium hydrogen carbonate, water, and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane-EtOAc 15:1 to 10:1) 5 to give 2-[1-(3-methoxy-2-methylbenzyl)-2-cyclohexen-2-yl]-4,5-diphenyloxazole (1.19 g) as an amorphous solid.

IR (KBr) : 3057, 2933, 2862, 1643, 1583, 1537, 1462,
1444, 1255 cm⁻¹

NMR (CDCl₃, δ) : 1.38-2.40 (6H, m), 2.42 (3H, s), 2.62
10 (1H, dd, J=13.1, 10.8Hz), 3.10-3.28 (1H, m), 3.35
(1H, dd, J=13.1, 3.8Hz), 3.80 (3H, s), 6.70 (1H, d,
J=7.9Hz), 6.82-6.95 (2H, m), 7.07 (1H, dd, J=7.9,
7.9Hz), 7.30-7.50 (6H, m), 7.58-7.77 (4H, m)

Mass (m/z) : 436 (M+H)⁺

15

Example 39

The following compounds described in (1) to (4) were obtained in a similar manner to that of Example 38.

20 (1) 2-[1-(3-Methoxy-4-methylbenzyl)-2-cyclohexen-2-yl]-4,5-diphenyloxazole

IR (neat) : 3053, 2933, 2860, 1610, 1585, 1533, 1506,
1446, 1411, 1255 cm⁻¹

NMR (CDCl₃, δ) : 1.40-1.90 (4H, m), 2.17 (3H, s), 2.18-
2.40 (2H, m), 2.52 (1H, dd, J=12.8, 9.9Hz), 3.06-
3.30 (2H, m), 3.79 (3H, s), 6.79 (1H, d, J=7.3Hz),
6.84-6.95 (2H, m), 7.03 (1H, d, J=7.3Hz), 7.23-7.42
(6H, m), 7.55-7.75 (4H, m)

Mass (m/z) : 436 (M+H)⁺

30

(2) 2-[1-(3-Methoxy-5-methylbenzyl)-2-cyclohexen-2-yl]-4,5-diphenyloxazole

IR (neat) : 3053, 2933, 2860, 1595, 1533, 1462, 1446,
1294, 1151 cm⁻¹

35 NMR (CDCl₃, δ) : 1.38-1.95 (4H, m), 2.10-2.58 (3H, m),

2.30 (3H, s), 3.08-3.27 (2H, m), 3.76 (3H, s), 6.55
(1H, s), 6.72 (1H, s), 6.77 (1H, s), 6.92 (1H, dd,
J=4.0, 4.0Hz), 7.23-7.45 (6H, m), 7.58-7.78 (4H, m)

Mass (m/z) : 436 (M+H)⁺

5

(3) 2-[1-(5-Methoxy-2-methylbenzyl)-2-cyclohexen-2-yl]-4,5-diphenyloxazole

IR (neat) : 3055, 2935, 2862, 1606, 1535, 1502, 1446,
1250 cm⁻¹

10 NMR (CDCl₃, δ) : 1.38-1.95 (4H, m), 2.07-2.47 (2H, m),
2.41 (3H, s), 2.60 (1H, dd, J=14.5, 12.0Hz), 3.10-
3.33 (2H, m), 3.75 (3H, s), 6.65 (1H, dd, J=8.4,
2.7Hz), 6.82-6.96 (2H, m), 7.04 (1H, d, J=8.4Hz),
7.20-7.43 (6H, m), 7.53-7.76 (4H, m)

15 Mass (m/z) : 436 (M+H)⁺

(4) 2-[1-(2-Methoxybenzyl)-2-cyclohexen-2-yl]-4,5-diphenyloxazole

IR (neat) : 3057, 2935, 2862, 1601, 1535, 1493, 1444,
20 1242 cm⁻¹

NMR (CDCl₃, δ) : 1.40-2.00 (4H, m), 2.10-2.38 (2H, m),
2.80 (1H, dd, J=12.9, 10.3Hz), 3.05-3.33 (2H, m),
3.78 (3H, s), 6.75-6.95 (3H, m), 7.07-7.43 (8H, m),
7.55-7.77 (4H, m)

25 Mass (m/z) : 422 (M+H)⁺

Example 40

To a solution of 2-[1-(3-methoxy-2-methylbenzyl)-2-cyclohexen-2-yl]-4,5-diphenyloxazole (1.16 g) in CH₂Cl₂ (25 ml) was added boron tribromide (1M solution in CH₂Cl₂, 5.32 ml) at -60°C and the mixture was warmed to 5°C. After stirring for 1 hour at the same temperature, the reaction mixture was stirred for further 1 hour at room temperature. To the mixture was added water under ice-cooling, extracted with EtOAc. The organic layer was washed with water,

saturated sodium hydrogen carbonate, water, and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane-EtOAc 5:1) to give 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-2-methylphenol (903.8 mg) as an amorphous solid.

IR (KBr) : 3330, 3059, 2933, 2862, 1645, 1585, 1537, 1466, 1446, 1273 cm^{-1}
 NMR (CDCl_3 , δ) : 1.35-2.40 (6H, m), 2.45 (3H, s), 2.60 (1H, dd, $J=13.3$, 11.1Hz), 3.07-3.25 (1H, m), 3.37 (1H, dd, $J=13.3$, 3.8Hz), 4.67 (1H, s), 6.62 (1H, d, $J=7.9\text{Hz}$), 6.80 (1H, d, $J=7.9\text{Hz}$), 6.85-7.02 (2H, m), 7.20-7.45 (6H, m), 7.55-7.75 (4H, m)
 Mass (m/z) : 422 ($M+\text{H}$)⁺

15 Example 41

The following compounds described in (1) to (4) were obtained in a similar manner to that of Example 40.

(1) 5-{{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}-2-methylphenol
 IR (KBr) : 3319, 3062, 2931, 2858, 1589, 1523, 1446, 1419, 1242, 1119 cm^{-1}
 NMR (CDCl_3 , δ) : 1.40-1.90 (4H, m), 2.08-2.36 (2H, m), 2.20 (3H, s), 2.47 (1H, dd, $J=12.7$, 9.9Hz), 3.05-3.27 (2H, m), 4.73 (1H, s), 6.70-6.83 (2H, m), 6.83-6.95 (1H, m), 7.02 (1H, d, $J=7.4\text{Hz}$), 7.22-7.45 (6H, m), 7.55-7.75 (4H, m)
 Mass (m/z) : 422 ($M+\text{H}$)⁺

30 (2) 3-{{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}-5-methylphenol
 IR (KBr) : 3330, 3032, 2931, 2858, 1595, 1535, 1444, 1311, 1298, 1153 cm^{-1}
 NMR (CDCl_3 , δ) : 1.40-1.90 (4H, m), 2.07-2.56 (3H, m), 2.27 (3H, s), 3.06-3.26 (2H, m), 4.82 (1H, s), 6.47

(1H, s), 6.61 (1H, s), 6.74 (1H, s), 6.92 (1H, dd,
J=4.0, 4.0Hz), 7.22-7.45 (6H, m), 7.55-7.77 (4H, m)

Mass (m/z) : 422 (M+H)⁺

5 (3) 3-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-
methyl}-4-methylphenol
IR (KBr) : 3356, 2935, 2862, 1606, 1587, 1535, 1502,
1444 cm⁻¹
NMR (CDCl₃, δ) : 1.38-1.98 (4H, m), 2.10-2.47 (2H, m),
2.40 (3H, s), 2.56 (1H, dd, J=14.3, 11.8Hz), 3.10-
3.33 (2H, m), 4.75 (1H, s), 6.57 (1H, dd, J=8.3,
2.7Hz), 6.76 (1H, d, J=2.7Hz), 6.91 (1H, dd, J=3.9,
3.9Hz), 6.98 (1H, d, J=8.3Hz), 7.20-7.43 (6H, m),
7.53-7.73 (4H, m)
Mass (m/z) : 422 (M+H)⁺

10 (4) 2-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-
methyl}phenol
IR (KBr) : 3180, 3057, 2937, 1645, 1579, 1535, 1485,
1446, 1344, 1227 cm⁻¹
NMR (CDCl₃, δ) : 1.30-2.00 (4H, m), 2.15-2.55 (3H, m),
2.82-2.98 (1H, m), 3.28-3.43 (1H, m), 6.72-7.50
(11H, m), 7.54-7.77 (4H, m)
Mass (m/z) : 408 (M+H)⁺

25

Example 42

To a solution of 3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-2-methylphenol (894 mg) and 2,6-lutidine (0.494 ml) in CH₂Cl₂ (18 ml) was added trifluoromethanesulfonic anhydride (0.534 ml) at 5°C and the mixture was stirred for 1 hour. The solvent was removed in vacuo and the residue was diluted with EtOAc, washed with water, 1N HCl, water, and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane-EtOAc 15:1) to give

3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-2-methylphenyl trifluoromethanesulfonate (960.8 mg) as an oil.

IR (neat) : 3059, 2939, 1537, 1448, 1419, 1250, 1217,
1140 cm⁻¹

5 NMR (CDCl₃, δ) : 1.40-1.95 (4H, m), 2.25-2.42 (2H, m),
2.54 (3H, s), 2.67 (1H, dd, J=13.4, 10.9Hz), 3.08-
3.25 (1H, m), 3.42 (1H, dd, J=13.4, 3.6Hz), 6.88-
6.95 (1H, m), 7.05-7.45 (9H, m), 7.55-7.74 (4H, m)
Mass (m/z) : 554 (M+H)⁺

10

Example 43

The following compounds described in (1) to (4) were obtained in a similar manner to that of Example 42.

15 (1) 5-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}-2-methylphenyl trifluoromethanesulfonate
IR (neat) : 3060, 2935, 2863, 1506, 1446, 1419, 1250,
1213, 1142, 1074 cm⁻¹
NMR (CDCl₃, δ) : 1.45-1.85 (4H, m), 2.08-2.46 (2H, m),
2.33 (3H, s), 2.56 (1H, dd, J=13.3, 10.4Hz), 3.05-
3.19 (1H, m), 3.22-3.35 (1H, m), 6.87-6.97 (1H, m),
7.15-7.44 (9H, m), 7.55-7.75 (4H, m)
Mass (m/z) : 554 (M+H)⁺

25 (2) 3-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}-5-methylphenyl trifluoromethanesulfonate
IR (neat) : 3059, 2935, 2864, 1620, 1585, 1533, 1446,
1421, 1240, 1213, 1142 cm⁻¹
NMR (CDCl₃, δ) : 1.40-1.90 (4H, m), 2.08-2.40 (2H, m),
2.36 (3H, s), 2.54 (1H, dd, J=13.2, 10.3Hz), 3.05-
3.35 (2H, m), 6.85-6.95 (2H, m), 7.08 (1H, s), 7.19
(1H, s), 7.23-7.47 (6H, m), 7.57-7.77 (4H, m)
Mass (m/z) : 554 (M+H)⁺

35 (3) 3-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-

methyl}-4-methylphenyl trifluoromethanesulfonate

IR (neat) : 3055, 2937, 2866, 1535, 1491, 1446, 1423,
1250, 1213, 1142 cm⁻¹

NMR (CDCl₃, δ) : 1.40-1.93 (4H, m), 2.18-2.50 (2H, m),
2.51 (3H, s), 2.63 (1H, dd, J=13.3, 11.0Hz), 3.08-
3.25 (1H, m), 3.35 (1H, dd, J=13.3, 3.7Hz), 6.93
(1H, dd, J=3.8, 3.8Hz), 6.99 (1H, dd, J=8.4,
2.7Hz), 7.15-7.23 (2H, m), 7.23-7.47 (6H, m), 7.55-
7.77 (4H, m)

Mass (m/z) : 554 (M+H)⁺

(4) 2-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-
methyl}phenyl trifluoromethanesulfonate

IR (neat) : 3059, 2937, 2866, 1533, 1487, 1448, 1419,
1248, 1215, 1140 cm⁻¹

NMR (CDCl₃, δ) : 1.40-2.00 (4H, m), 2.10-2.50 (2H, m),
2.94 (1H, dd, J=14.5, 10.7Hz), 3.14-3.34 (2H, m),
6.87-6.98 (1H, m), 7.10-7.78 (14H, m)

Mass (m/z) : 540 (M+H)⁺

20

Example 44

A mixture of 3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-2-methylphenyl trifluoromethanesulfonate (955 mg), palladium(II) acetate (117 mg), 1,3-bis(diphenylphosphino)propane (214 mg), triethylamine (0.72 ml), and MeOH (6 ml) in DMF (12 ml) was purged for 30 minutes with carbon monoxide. The mixture was stirred under carbon monoxide atmosphere at 95°C for 1 hour. After cooling to room temperature, the reaction mixture was diluted with EtOAc, washed with water, 1N HCl, water, saturated sodium hydrogen carbonate, water, and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane-EtOAc 13:1) to give methyl 3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-2-methylbenzoate (226.3 mg) as an

30

35

amorphous solid.

IR (KBr) : 3064, 2937, 2862, 1722, 1537, 1448, 1257 cm⁻¹
NMR (CDCl₃, δ) : 1.38-2.00 (4H, m), 2.10-2.50 (2H, m),
2.57-2.75 (1H, m), 2.73 (3H, s), 3.10-3.30 (1H, m),
3.43 (1H, dd, J=13.6, 4.1Hz), 3.88 (3H, s), 6.91
(1H, dd, J=3.9, 3.9Hz), 7.13 (1H, dd, J=7.6,
7.6Hz), 7.25-7.43 (7H, m), 7.55-7.75 (5H, m)
Mass (m/z) : 464 (M+H)⁺

10 Example 45

The following compounds described in (1) to (4) were obtained in a similar manner to that of Example 44.

(1) Methyl 5-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-
15 yl]methyl}-2-methylbenzoate
IR (KBr) : 3055, 2933, 2860, 1722, 1536, 1500, 1444,
1290, 1259 cm⁻¹
NMR (CDCl₃, δ) : 1.40-1.90 (4H, m), 2.10-2.38 (2H, m),
2.54 (3H, s), 2.58 (1H, dd, J=13.2, 10.3Hz), 3.07-
20 3.35 (2H, m), 3.85 (3H, s), 6.88-6.97 (1H, m), 7.16
(1H, d, J=7.8Hz), 7.22-7.43 (7H, m), 7.55-7.75 (4H,
m), 7.87 (1H, d, J=0.9Hz)
Mass (m/z) : 464 (M+H)⁺

25 (2) Methyl 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-
yl]methyl}-5-methylbenzoate
IR (KBr) : 3059, 2933, 2860, 1720, 1604, 1537, 1444,
1309, 1219 cm⁻¹
NMR (CDCl₃, δ) : 1.35-1.95 (4H, m), 2.10-2.45 (2H, m),
2.35 (3H, s), 2.58 (1H, dd, J=12.7, 9.5Hz), 3.10-
30 3.33 (2H, m), 3.87 (3H, s), 6.92 (1H, dd, J=3.9,
3.9Hz), 7.25-7.46 (7H, m), 7.58-7.77 (5H, m), 7.79
(1H, s)
Mass (m/z) : 464 (M+H)⁺

(3) Methyl 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-4-methylbenzoate

IR (KBr) : 3045, 2935, 2862, 1718, 1606, 1537, 1439,
1296, 1267 cm⁻¹

NMR (CDCl₃, δ) : 1.42-2.04 (4H, m), 2.20-2.45 (2H, m),
2.56 (3H, s), 2.67 (1H, dd, J=13.2, 10.3Hz), 3.10-
3.30 (1H, m), 3.35 (1H, dd, J=13.2, 4.2Hz), 3.85
(3H, s), 6.83-6.93 (1H, m), 7.18 (1H, d, J=8.0Hz),
7.21-7.45 (6H, m), 7.54-7.78 (5H, m), 7.91 (1H, d,
J=1.7Hz)

Mass (m/z) : 464 (M+H)⁺

(4) Methyl 2-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoate

IR (neat) : 3057, 2935, 2862, 1722, 1603, 1533, 1487,
1446, 1261 cm⁻¹

NMR (CDCl₃, δ) : 1.40-2.00 (4H, m), 2.10-2.50 (2H, m),
3.20-3.43 (3H, m), 3.86 (3H, s), 6.88-6.98 (1H, m),
7.10-7.80 (14H, m)

Mass (m/z) : 450 (M+H)⁺

Example 46

A mixture of 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl]methyl}phenyl trifluoromethanesulfonate (400 mg), 3-methoxycarbonylphenylboronic acid (177 mg), triethylamine (0.318 ml), and tetrakis(triphenylphosphine)palladium(0) (64 mg) in DMF (8 ml) was stirred at 100°C for 3.5 hours. After cooling to room temperature, the reaction mixture was diluted with EtOAc, washed with water, 1N HCl, water, saturated sodium hydrogen carbonate, water, and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane-EtOAc 10:1) to give methyl 3'-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl]-methyl}biphenyl-3-carboxylate (264.6 mg) as an oil.

IR (neat) : 3057, 2949, 2843, 1724, 1603, 1441, 1308,
1252 cm⁻¹

NMR (CDCl₃, δ) : 1.80-2.20 (2H, m), 2.39-2.54 (2H, m),
2.75 (1H, dd, J=13.4, 9.1Hz), 3.45 (1H, dd, J=13.4,
4.3Hz), 3.52-3.72 (1H, m), 3.93 (3H, s), 6.68-6.76
(1H, m), 7.23-7.78 (16H, m), 7.95-8.05 (1H, m),
8.23-8.30 (1H, m)

Mass (m/z) : 512 (M+H)⁺

10 Example 47

To a solution of methyl 3-{{[2-(4,5-diphenyloxazol-2-yl)-
2-cyclohexen-1-yl]methyl}-2-methylbenzoate (119 mg) in EtOAc
(8 ml) and MeOH (10 ml) was added 10% Pd/C (wet) (60 mg) and
the mixture was stirred under hydrogen atmosphere at 3 atm at
15 room temperature for 18 hours. The catalyst was removed by
filtration and the filtrate was evaporated to give methyl 3-
{{[2-(4,5-diphenyloxazol-2-yl)-1-cyclohexyl]methyl}-2-methyl-
benzoate (115.3 mg) as an amorphous solid.

IR (KBr) : 3064, 2929, 2854, 1720, 1560, 1502, 1446,
20 1261 cm⁻¹

NMR (CDCl₃, δ) : 1.00-2.90 and 3.18-3.33 (total 12H,
each m), 2.41 and 2.42 (total 3H, each s), 3.84 and
3.86 (total 3H, each s), 6.98-7.73 (13H, m)

Mass (m/z) : 466 (M+H)⁺

25

Example 48

The following compounds described in (1) to (3) were
obtained in a similar manner to that of Example 47.

- 30 (1) Methyl 5-{{[2-(4,5-diphenyloxazol-2-yl)-1-cyclohexyl]-
methyl}-2-methylbenzoate
- IR (neat) : 3057, 2929, 2854, 1722, 1604, 1563, 1500,
1446, 1261, 1200 cm⁻¹
- NMR (CDCl₃, δ) : 1.00-2.80 and 3.15-3.28 (total 12H,
each m), 2.45 and 2.50 (total 3H, each s), 3.77 and

3.79 (total 3H, each s), 7.00-7.73 (13H, m)

Mass (m/z) : 466 (M+H)⁺

(2) Methyl 3-{{2-(4,5-diphenyloxazol-2-yl)-1-cyclohexyl}-

5 methyl}-5-methylbenzoate

IR (neat) : 3057, 2929, 2854, 1722, 1604, 1564, 1446,
1309, 1219 cm⁻¹

NMR (CDCl₃, δ) : 1.05-2.80 and 3.15-3.26 (total 12H,
each m), 2.21 and 2.27 (total 3H, each s), 3.79 and
10 3.82 (total 3H, each s), 7.10 (1H, br s), 7.20-7.73
(12H, m)

Mass (m/z) : 466 (M+H)⁺

(3) Methyl 3-{{2-(4,5-diphenyloxazol-2-yl)-1-cyclohexyl}-

15 methyl}-4-methylbenzoate

IR (neat) : 3057, 2931, 2856, 1720, 1606, 1566, 1444,
1296, 1269 cm⁻¹

NMR (CDCl₃, δ) : 1.03-2.85 and 3.18-3.33 (total 12H,
each m), 2.27 and 2.28 (total 3H, each s), 3.79 and
20 3.80 (total 3H, each s), 7.03-7.17 (1H, m), 7.22-
7.88 (12H, m)

Mass (m/z) : 466 (M+H)⁺

Example 49

25 A mixture of methyl 3'-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl}methyl}biphenyl-3-carboxylate (204 mg) and 10% Pd/C (wet) (50 mg) in EtOAc (3 ml) and MeOH (3 ml) was stirred under hydrogen atmosphere at room temperature for 14 hours. The catalyst was removed by filtration and the
30 filtrate was evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane-EtOAc 12:1 to 6:1) to give methyl 3'-{{2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl}methyl}biphenyl-3-carboxylate (172.1 mg) as an oil.

35 IR (neat) : 3057, 2951, 2871, 1724, 1604, 2566, 1442,

63

1308, 1252 cm^{-1}

NMR (CDCl_3 , δ) : 1.38-2.38 (6H, m), 2.41-3.10 and
3.44-3.48 (total 4H, each m), 3.92 and 3.93 (total
3H, each s), 7.10-7.73 (16H, m), 7.92-8.02 (1H, m),
8.14-8.23 (1H, m)

Mass (m/z) : 514 ($\text{M}+\text{H}$)⁺Example 50

To a solution of methyl 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-2-methylbenzoate (100 mg) in MeOH-1,4-dioxane (1:2, 4.5 ml) was added 1N NaOH solution (1.0 ml) and the mixture was stirred at 70°C for 1 hour. After cooling, the mixture was acidified with 1N HCl and extracted with EtOAc. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo to give 3-{{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}-2-methylbenzoic acid (97.0 mg) as a solid.

IR (KBr) : 3059, 2935, 2860, 2646, 1685, 1587, 1539,
1446, 1302, 1269 cm^{-1}

NMR (DMSO-d_6 , δ) : 1.30-2.05 (4H, m), 2.05-2.50 (2H, m),
2.55-2.75 (1H, m), 2.65 (3H, s), 2.93-3.17 (1H, m),
3.18-3.45 (1H, m), 6.85-6.95 (1H, m), 7.19 (1H, dd,
 $J=7.5, 7.5\text{Hz}$), 7.30-7.70 (12H, m), 12.80 (1H, br)

Mass (m/z) : 450 ($\text{M}+\text{H}$)⁺

25

Example 51

The following compounds described in (1) to (9) were obtained in a similar manner to that of Example 50.

(1) 3-{{[2-(4,5-Diphenyloxazol-2-yl)-1-cyclohexyl]methyl}-2-methylbenzoic acid

IR (KBr) : 3059, 2929, 2854, 2642, 1689, 1560, 1446,
1240 cm^{-1}

NMR (CDCl_3 , δ) : 1.00-2.95 and 3.20-3.33 (total 12H,
each m), 2.50 (3H, s), 7.00-7.80 (13H, m)

35

Mass (m/z) : 452 (M+H)⁺

(2) 5-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-
5 methyl}-2-methylbenzoic acid

IR (KBr) : 3026, 2931, 2860, 2654, 1689, 1604, 1570,
1533, 1500, 1446, 1267 cm⁻¹
NMR (DMSO-d₆, δ) : 1.35-1.95 (4H, m), 2.06-2.70 (3H, m),
2.47 (3H, s), 2.90-3.30 (2H, m), 6.83-6.97 (1H, m),
7.22 (1H, d, J=7.8Hz), 7.27-7.74 (11H, m), 8.00
10 (1H, s), 12.79 (1H, br)

Mass (m/z) : 450 (M+H)⁺

(3) 5-{[2-(4,5-Diphenyloxazol-2-yl)-1-cyclohexyl]methyl}-2-
methylbenzoic acid

15 IR (KBr) : 3057, 2927, 2854, 1687, 1606, 1562, 1500,
1446, 1254 cm⁻¹
NMR (CDCl₃, δ) : 1.00-2.87 and 3.17-3.30 (total 12H,
each m), 2.52 and 2.57 (total 3H, each s), 7.03-
7.90 (13H, m)

20 Mass (m/z) : 452 (M+H)⁺

(4) 3-{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-
methyl}-5-methylbenzoic acid

25 IR (KBr) : 3049, 2933, 2860, 1682, 1603, 1529, 1446,
1309, 1244 cm⁻¹
NMR (DMSO-d₆, δ) : 1.30-1.98 (4H, m), 2.08-2.70 (3H, m),
2.32 (3H, s), 2.93-3.25 (2H, m), 6.85-6.95 (1H, m),
7.30-7.73 (12H, m), 7.77 (1H, s), 12.84 (1H, br)
Mass (m/z) : 450 (M+H)⁺

30 (5) 3-{[2-(4,5-Diphenyloxazol-2-yl)-1-cyclohexyl]methyl}-5-
methylbenzoic acid
IR (KBr) : 3059, 2927, 2854, 1687, 1604, 1560, 1446,
1308, 1240 cm⁻¹
NMR (CDCl₃, δ) : 1.00-2.85 and 3.18-3.32 (total 12H,

each m), 2.24 and 2.30 (total 3H, each s), 7.16
(1H, br s), 7.20-7.75 (12H, m)

Mass (m/z) : 452 (M+H)⁺

- 5 (6) 3-{{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-
methyl}-4-methylbenzoic acid
IR (KBr) : 3028, 2931, 2864, 1689, 1610, 1576, 1537,
1446, 1425, 1309, 1279 cm⁻¹
NMR (DMSO-d₆, δ) : 1.40-2.00 (4H, m), 2.10-2.43 (2H, m),
2.51 (3H, s), 2.60-2.78 (1H, m), 3.00-3.40 (2H, m),
6.88-6.97 (1H, m), 7.25 (1H, d, J=7.9Hz), 7.33-7.74
(11H, m), 7.87 (1H, s)
Mass (m/z) : 450 (M+H)⁺

- 15 (7) 3-{{[2-(4,5-Diphenyloxazol-2-yl)-1-cyclohexyl]methyl}-4-
methylbenzoic acid
IR (KBr) : 3056, 2929, 2856, 1687, 1608, 1560, 1446,
1273, 1242 cm⁻¹
NMR (CDCl₃, δ) : 1.05-2.88 and 3.18-3.33 (total 12H,
each m), 2.29 and 2.30 (total 3H, each s), 7.07-
7.20 (1H, m), 7.20-7.95 (12H, m)
Mass (m/z) : 452 (M+H)⁺

- 25 (8) 3'-{{[2-(4,5-Diphenyloxazol-2-yl)-2-cyclopenten-1-yl]-
methyl}biphenyl-3-carboxylic acid
IR (KBr) : 3055, 2929, 1691, 1603, 1543, 1444, 1306,
1240 cm⁻¹
NMR (DMSO-d₆, δ) : 1.60-2.20 (2H, m), 2.35-2.58 (2H, m),
2.65-2.83 (1H, m), 3.10-3.85 (2H, m), 6.70-6.77
(1H, m), 7.20-7.98 (17H, m), 8.18 (1H, s)
Mass (m/z) : 498 (M+H)⁺

- 35 (9) 3'-{{[2-(4,5-Diphenyloxazol-2-yl)-1-cyclopentyl]methyl}-
biphenyl-3-carboxylic acid
IR (KBr) : 3055, 2952, 2870, 1691, 1603, 1560, 1444,

66

1306, 1240 cm^{-1}

NMR (DMSO-d₆, δ) : 1.35-2.25 (6H, m), 2.50-3.60 (4H, m),
7.11-7.58 (15H, m), 7.68-7.80 (1H, m), 7.80-7.93
(1H, m), 8.07-8.17 (1H, m)

5 Mass (m/z) : 500 (M+H)⁺Example 52

To a solution of methyl 2-[(2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl)methyl]benzoate (37 mg) in MeOH-1,4-dioxane (1:1, 3 ml) was added 1N NaOH solution (1.0 ml) at 5°C and the mixture was stirred at 80°C for 3 hours. After cooling, the mixture was acidified with 1N HCl and extracted with EtOAc. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was dissolved in MeOH-1,4-dioxane (1:1, 2 ml) and 1N NaOH solution (0.0824 ml) was added thereto. The mixture was evaporated and Et₂O was added. The resulting solid was collected by filtration to give sodium 2-[(2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl)methyl]benzoate (19.9 mg).

20 IR (KBr) : 3421, 3057, 2929, 1603, 1579, 1558, 1442,
1406 cm^{-1} 25 NMR (DMSO-d₆, δ) : 1.20-2.43 (6H, m), 2.80-3.20 (2H, m),
3.55-3.73 (1H, m), 6.80-6.90 (1H, m), 6.93-7.15
(2H, m), 7.20-7.53 (8H, m), 7.55-7.70 (4H, m)Mass (m/z) : 458 (M+H)⁺Example 53

To a solution of 3'-(2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl)methyl biphenyl-3-carboxylic acid (74 mg) and N-methylmorpholine (0.0197 ml) in THF (4 ml) was added isobutyl chloroformate (0.0232 ml) at 0°C. After stirring for 15 minutes, 28% ammonia solution (0.1 ml) was added thereto. The mixture was stirred at the same temperature for 15 minutes, then stirred at room temperature for 15 minutes.

The reaction mixture was diluted with EtOAc, washed with water, 1N HCl, water, and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was purified by silica gel column chromatography (CH_2Cl_2 -MeOH 25:1) to give 5 3'-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl]methyl}- biphenyl-3-carboxamide (51.8 mg) as a solid.

IR (KBr) : 3375, 3182, 3060, 1647, 1587, 1523, 1444,
1406 cm^{-1}
NMR (DMSO-d_6 , δ) : 1.75-2.20 (2H, m), 2.35-2.55 (2H, m),
10 2.74 (1H, dd, $J=13.3, 9.2\text{Hz}$), 3.25-3.43 (2H, m),
6.70-6.78 (1H, m), 7.20-7.70 (16H, m), 7.70-7.90
(2H, m), 8.05-8.20 (2H, m)
Mass (m/z) : 497 (M+H^+)

15 Example 54

The following compound was obtained in a similar manner to that of Example 53.

3'-{[2-(4,5-Diphenyloxazol-2-yl)-1-cyclopentyl]methyl}-
20 biphenyl-3-carboxamide
IR (neat) : 3348, 3194, 3059, 2958, 2871, 1666, 1603,
1577, 1446, 1408, 1383 cm^{-1}
NMR (CDCl_3 , δ) : 1.40-3.15 and 3.40-3.58 (total 10H,
each m), 7.10-7.68 (16H, m), 7.70-7.80 (1H, m),
25 7.90-7.95 (1H, m)
Mass (m/z) : 499 (M+H^+)

Example 55

To a solution of 4-bromoanisole (1.00 g) in
30 tetrahydrofuran (4 ml), n-butyllithium hexane solution
(1.56M, 3.4 ml) was added at -78°C under a flow of nitrogen.
After stirring for 0.5 hour, a solution of 2-[$(4,5-$
diphenyloxazol-2-yl)methyl]cyclohexan-1-one (1.36 g) in
tetrahydrofuran (3 ml) was added below -50°C to the reaction
35 mixture and stirred for 0.5 hour. After usual workup, the

crude product was purified by column chromatography (silica gel 50 g, eluent; hexane/ethyl acetate = 9 then 4) to give 2-[(4,5-diphenyloxazol-2-yl)methyl]-1-(3-methoxyphenyl)-1-cyclohexanol (1.01 g) as a foam.

5 IR (film) : 3420, 2935, 1604, 1581, 1484, 1446, 1288,
1249, 1160, 1056, 1047, 964, 775, 696 cm⁻¹
NMR (CDCl₃, δ) : 1.3-2.0 (10H, m), 2.38-2.58 (1H, m),
2.68 (2H, d, J=6.1Hz), 3.78 (3H, s), 6.70-6.76 (1H,
m), 7.08-7.45 (9H, m), 7.49-7.63 (4H, m)
10 Mass (m/z) : 440 (M+H)⁺, 422

Example 56

15 A mixture of 2-[(4,5-diphenyloxazol-2-yl)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol (990 mg), p-toluenesulfonic acid monohydrate (22 mg) and acetic acid (5 ml) was heated at 130°C for 6 hours. After usual workup and purification by column chromatography (silica gel, 45 g, eluent; hexane/ethyl acetate = 9), 1-[(4,5-diphenyloxazol-2-yl)methyl]-2-(3-methoxyphenyl)-2-cyclohexene (551 mg) as a pasty solid.

20 IR (film) : 2931, 1602, 1574, 1487, 1454, 1429, 1286,
1205, 1171, 1057, 962, 764, 694 cm⁻¹
NMR (CDCl₃, δ) : 1.63-1.80 (2H, m), 1.80-1.92 (2H, m),
2.15-2.29 (2H, m), 2.75 (1H, dd, J=9.5, 14.9Hz),
2.93 (1H, dd, J=5.0, 14.9Hz), 3.32-3.50 (1H, m),
3.73 (3H, s), 6.00-6.04 (1H, m), 6.68-6.76 (1H, m),
25 6.88-6.99 (2H, m), 7.14 (1H, t, J=7.9Hz), 7.28-7.42
(6H, m), 7.48-7.62 (4H, m)
Mass (m/z) : 422 (M+H)⁺

30 Example 57

The following compounds described in (1) to (2) were prepared in a similar manner to that of Example 38.

35 (1) A mixture of 3-(4,5-diphenyloxazol-2-yl)-1-(3-methoxybenzyl)-2-cyclohexene and 3-(4,5-diphenyloxazol-

2-yl)-1-(3-methoxybenzyl)-3-cyclohexene

IR (film) : 2929, 1601, 1585, 1487, 1448, 1261, 1153,
1061, 1043, 964, 766, 694 cm⁻¹

NMR (CDCl₃, δ) : 1.3-1.4 (1H, m), 1.7-2.1 (2H, m), 2.1-
2.4 (2H, m), 2.50-2.92 (4H, m), 3.81 (3H, s), 6.72-
6.96 (4H, m), 7.18-7.45 (7H, m), 7.54-7.72 (4H, m)

Mass (m/z) : 422 (M+H)⁺

5

- (2) A mixture of 3-(4,5-diphenyloxazol-2-yl)-1-(3-methoxyphenyl)-2-cyclohexene and 3-(4,5-diphenyloxazol-2-yl)-1-(3-methoxyphenyl)-3-cyclohexene

10

Example 58

The following compounds described in (1) to (2) were
15 obtained in a similar manner to that of Example 22.

- (1) A mixture of methyl 3-{[3-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoate and methyl 3-{[3-(4,5-diphenyloxazol-2-yl)-3-cyclohexen-1-yl]methyl}benzoate

20

IR (film) : 2929, 1722, 1537, 1446, 1284, 1203, 1107,
964, 764, 696 cm⁻¹
NMR (CDCl₃, δ) : 1.3-1.5 (1H, m), 1.7-2.4 (4H, m), 2.5-
2.9 (4H), 3.91 (3H, s), 6.78 (0.4H, br s), 6.88
(0.6H, br s), 7.30-7.48 (8H, m), 7.56-7.70 (4H, m),
7.86-7.96 (2H, m)

25

Mass (m/z) : 450 (M+H)⁺

- (2) A mixture of methyl 3-[3-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]benzoate and methyl 3-[3-(4,5-diphenyloxazol-2-yl)-3-cyclohexen-1-yl]benzoate

30

IR (film) : 2931, 1718, 1537, 1444, 1286, 1196, 1109,
964, 756, 694 cm⁻¹
NMR (CDCl₃, δ) : 1.5-2.2 (3H, m), 2.42-3.16 (4H, m),
3.92 (3H, s), 6.89 (0.4H, br s), 6.97 (0.6H, br s),
7.25-7.53 (8H, m), 7.53-7.73 (4H, m), 7.88-8.02

35

(2H, m)

Mass (m/z) : 436 (M+H)⁺(3) Methyl 3-{1-[(4,5-diphenyloxazol-2-yl)methyl]-2-
5 cyclohexen-2-yl}benzoateIR (film) : 2933, 1726, 1720, 1579, 1442, 1292, 1227,
1110, 1061, 964, 762, 696 cm⁻¹NMR (CDCl₃, δ) : 1.67-1.82 (2H, m), 1.84-1.95 (2H, m),
2.20-2.40 (2H, m), 2.79 (1H, dd, J=8.5, 14.7Hz),
2.92 (1H, dd, J=6.2, 14.7Hz), 3.40-3.53 (1H, m),
3.81 (3H, s), 6.03 (1H, dt, J=0.7, 3.2Hz), 7.21-
7.40 (7H, m), 7.42-7.56 (4H, m), 7.80 (1H, d,
J=7.4Hz), 8.00 (1H, d, J=1.7Hz)Mass (m/z) : 450 (M+H)⁺

15

Example 59The following compounds described in (1) to (3) were prepared in a similar manner to that of Example 24.20 (1) A mixture of 3-{[3-(4,5-diphenyloxazol-2-yl)-2-
cyclohexen-1-yl]methyl}benzoic acid and 3-{[3-(4,5-
diphenyloxazol-2-yl)-3-cyclohexen-1-yl]methyl}benzoic
acidIR (KBr) : 3432, 2924, 1695, 1535, 1446, 1298, 1211,
25 1074, 964, 764, 692 cm⁻¹NMR (CDCl₃, δ) : 1.3-1.5 (1H, m), 1.5-2.4 (4H, m), 2.5-
2.9 (4H, m), 6.79 (0.4H, br s), 6.88 (0.6H, br s),
7.3-7.7 (12H, m), 7.9-8.0 (2H, m)Mass (m/z) : 436 (M+H)⁺

30

(2) A mixture of 3-[3-(4,5-diphenyloxazol-2-yl)-2-
cyclohexen-1-yl]benzoic acid and 3-[3-(4,5-
diphenyloxazol-2-yl)-3-cyclohexen-1-yl]benzoic acid.IR (film) : 3435, 2927, 1693, 1446, 1292, 1076, 966,
35 764, 694 cm⁻¹

NMR (CDCl_3 , δ) : 1.5-2.2 (3H, m), 2.4-3.18 (4H, m), 6.90 (0.4H, br s), 6.97 (0.6H, br s), 7.3-7.74 (12H, m), 7.90-8.06 (2H, m)
Mass (m/z) : 422 ($\text{M}+\text{H}$)⁺

5

(3) 3-{1-[(4,5-Diphenyloxazol-2-yl)methyl]-2-cyclohexen-2-yl}benzoic acid

IR (KBr) : 3448, 2925, 1709, 1444, 1282, 1224, 1063, 760, 694 cm^{-1}

10

NMR (CDCl_3 , δ) : 1.56-1.90 (4H, m), 2.12-2.27 (2H, m), 2.78 (2H, d, $J=6.5\text{Hz}$), 3.3-3.46 (7H, m), 6.04 (1H, t, $J=3.3\text{Hz}$), 7.3-7.6 (12H, m), 7.73 (1H, d, $J=7.7\text{Hz}$), 7.92 (1H, s), 12.9 (1H, br s)

Mass (m/z) : 436 ($\text{M}+\text{H}$)⁺

15

Example 60

The following compounds described in (1) to (5) were obtained in a similar manner to those of Example 22 and Example 24.

20

(1) 4-{{2-(4,5-Diphenyloxazol-2-yl)-2-cyclohepten-1-yl}-methyl}benzoic acid

NMR (CDCl_3 , δ) : 1.4-2.0 (6H, m), 2.3-2.6 (2H, m), 2.98 (1H, m), 3.05 (1H, m), 3.82 (1H, m), 7.09 (1H, t, $J=8.0\text{Hz}$), 7.2-8.2 (14H, m)

25

Mass (m/z) : 450 ($\text{M}+\text{H}$)⁺

(2) 4-{{3-(4,5-Diphenyloxazol-2-yl)bicyclo[2.2.1]hept-2-en-2-yl}methyl}benzoic acid

30

IR (Nujol) : 1700 cm^{-1}

NMR (CDCl_3 , δ) : 1.0-2.0 (6H, m), 2.82 (1H, br s), 3.62 (1H, br s), 3.70 (1H, d, $J=14\text{Hz}$), 4.40 (1H, d, $J=14\text{Hz}$), 7.2-8.1 (14H, m)

Mass (m/z) : 448 ($\text{M}+\text{H}$)⁺

35

(3) 3-[{2-(4,5-Diphenyloxazol-2-yl)-2-cycloocten-1-yl}-methyl]benzoic acid
 Mass (m/z) : 464 (M+H)⁺

5 (4) 4-[{2-(4,5-Diphenyloxazol-2-yl)-2-cyclopenten-1-yl}-methyl]benzoic acid
 IR (Nujol) : 1680 cm⁻¹
 NMR (CDCl₃, δ) : 1.8-2.2 (2H, m), 2.3-2.5 (2H, m), 2.72
 (1H, dd, J=9, 14Hz), 2.99 (2H, m), 3.48 (1H, dd,
 10 J=5, 15Hz), 3.60 (1H, m), 6.71 (1H, m), 7.2-8.1
 (14H, m)
 Mass (m/z) : 422 (M+H)⁺

15 (5) 3-[{2-[4,5-Di(4-methylphenyl)oxazol-2-yl]-2-cyclohexen-1-yl}methyl]benzoic acid
 IR (Nujol) : 1680 cm⁻¹
 NMR (CDCl₃, δ) : 1.5-2.4 (6H, m), 2.33 (6H, s), 2.60
 (1H, m), 3.1-3.4 (2H, m), 6.90 (1H, m), 7.0-8.2
 (14H, m)
 20 Mass (m/z) : 464 (M+H)⁺

25 (6) 3-[{2-(4,5-Diphenylthiazol-2-yl)-2-cyclohexen-1-yl}-methyl]benzoic acid
 IR (Nujol) : 1680 cm⁻¹
 NMR (CDCl₃, δ) : 1.3-2.8 (7H, m), 3.2-3.4 (2H, m), 6.64
 (1H, m), 7.2-8.2 (14H, m)
 Mass (m/z) : 452 (M+H)⁺

Example 61

30 The following compounds described in (1) to (2) were obtained according to a similar manner to that of Example 29.

35 (1) 4-[{3-(4,5-Diphenyloxazol-2-yl)bicyclo[2.2.1]heptan-2-yl}methyl]benzoic acid
 Mass (m/z) : 450 (M⁺+H)⁺

73

(2) 4-[{2-(4,5-Diphenyloxazol-2-yl)-1-cyclopentyl}methyl]-
benzoic acid

IR (Nujol) : 1650 cm⁻¹

NMR (CDCl₃, δ) : 1.5-2.9 (9H, m), 3.48 (1H, m),
7.2-8.0 (14H, m)

5

Mass (m/z) : 423 (M+H)⁺

10

15

20

25


30

35

C L A I M S

1. A compound of the formula :

5



wherein

10 R^1 is lower alkyl substituted with hydroxy, protected carboxy or carboxy; carboxy; protected carboxy; carbamoyl; a heterocyclic group; cyano; halo(lower)alkylsulfonyloxy; lower alkoxy substituted with hydroxy or carbamoyl; aryl substituted with carboxy, protected carboxy, carbamoyl or a heterocyclic group; or amino optionally substituted with protected carboxy or lower alkylsulfonyl,

15 R^2 is hydrogen or lower alkyl,

20 R^3 is aryl optionally substituted with halogen,

25 R^4 is aryl optionally substituted with halogen,

Q is $-A^1 - \text{C}(\text{A}^2)=A^3-$ [in which $-A^1-$ is a single bond or lower alkylene, $\text{C}(\text{A}^2)=$ is cyclo(C_5-C_9)alkene, cyclo(C_3-C_9)alkane, bicyclo(C_6-C_9)alkene or bicyclo(C_5-C_9)alkane, and $-A^3-$ is a single bond or lower alkylene], and

30 X is O, NH or S,

and its salt.

30

2. A compound according to the claim 1, wherein

35 X is O.

3. A compound according to the claim 2, wherein

35 R^1 is lower alkyl substituted with carboxy; carboxy;

protected carboxy; carbamoyl; a heterocyclic group; lower alkoxy substituted with carbamoyl; aryl substituted with carboxy, carbamoyl or a heterocyclic group; or amino optionally substituted with lower alkylsulfonyl.

5

4. A compound according to the claim 3, wherein R¹ is lower alkyl substituted with carboxy; carboxy; carbamoyl; tetrazolyl; lower alkoxy substituted with carbamoyl; aryl substituted with carboxy or carbamoyl, and


10

Q is $-A^1 - \text{circle} - A^3 -$ [in which -A¹- is methylene, circle_{A^2} is cyclo(C₅-C₇)alkene, cyclo(C₅-C₇)alkane, bicyclo[2.2.1]heptene or bicyclo[2.2.1]heptane, and -A³- is a single bond].

15

5. A process for production of the compound of the formula :

20



wherein

25

R¹ is lower alkyl substituted with hydroxy, protected carboxy or carboxy; carboxy; protected carboxy; carbamoyl; a heterocyclic group; cyano; halo(lower)alkylsulfonyloxy; lower alkoxy substituted with hydroxy or carbamoyl; aryl substituted with carboxy, protected carboxy, carbamoyl or a heterocyclic group; or amino optionally substituted with protected carboxy or lower alkylsulfonyl,

30

R² is hydrogen or lower alkyl,

35

R³ is aryl optionally substituted with halogen,


R^4 is aryl optionally substituted with halogen,

Q is $-A^1 - \begin{array}{c} \text{O} \\ | \\ A^2 \end{array} - A^3 -$ [in which $-A^1-$ is a single bond or lower alkylene, A^2 is cyclo(C₅-C₉)alkene, cyclo(C₃-C₉)alkane, bicyclo(C₆-C₉)alkene or bicyclo(C₅-C₉)alkane, and $-A^3-$ is a single bond or lower alkylene], and


X is O, NH or S,
or its salt, which comprises,

10

(1) dehydrating a compound of the formula :



15 or its salt, to give a compound of the formula :



or its salt, in the above formulas,


20 R^1 , R^2 , R^3 , R^4 , $-A^1-$, $-A^3-$ and X are each as defined above,

A^2_a is cyclo(C₅-C₉)alkene or bicyclo(C₆-C₉)alkene,
and,
 A^4_a is cyclo(C₅-C₉)alkane or bicyclo(C₆-C₉)alkane,
each of which is substituted with hydroxy,

25

(2) reducing the compound of the formula (I-1) defined above, or its salt, to give a compound of the formula :

30




35

or its salt, in the above formula, R^1 , R^2 , R^3 , R^4 , $-A^1-$, $-A^3-$ and X are each as defined above, and

A_2^{b} is cyclo(C₅-C₉)alkane or bicyclo(C₆-C₉)alkane,

- (3) subjecting a compound of the formula :

5



10

or its salt, to (a) a cleavage of ether bond and
 (b) a halo(lower)alkylsulfonylation, to give a
 compound of the formula :


15

or its salt, in the above formulas,
 R², R³, R⁴, Q and X are each as defined above,
 R¹_a is lower alkoxy, and
 R¹_b is halo(lower)alkylsulfonyloxy,

20

- (4) subjecting the compound of the formula (I-4)
 defined above, or its salt, to Pd-catalyzed
 carbonylation, to give a compound of the formula :

25




30

or its salt, in the above formula,
 R², R³, R⁴, Q and X are each as defined above, and
 R¹_c is protected carboxy,

35

- (5) subjecting the compound of the formula (I-5)
 defined above, or its salt, to deesterification, to
 give a compound of the formula :




or its salt, in the above formula,

5 R^2 , R^3 , R^4 , Q and X are each as defined above, and
 R_d^1 is carboxy,

- (6) reacting the compound of the formula (I-6) defined above, or its reactive derivative at the carboxy group, or its salt, with a compound of the formula :




or its reactive derivative, or its salt, to give a compound of the formula :



20 or its salt, in the above formulas,
 R^2 , R^3 , R^4 , Q and X are each as defined above, and
 R_e^1 is carbamoyl.

- 25 (7) reacting the compound of the formula (I-5) defined above, or its salt, with the compound of the formula (III) defined above, or its salt, to give the compound of the formula (I-7) or its salt, or,


- (8) reacting a compound of the formula :



35 or its reactive derivative at carboxy group, or its salt, with the compound of the formula (III)

defined above, or its reactive derivative, or its salt, to give a compound of the formula :

5



10

or its salt, in the above formula,
 R^2 , R^3 , R^4 , Q and X are each as defined above,
 R_f^1 is lower alkoxy substituted with carbamoyl, and
 R^5 is lower alkoxy substituted with carboxy or
protected carboxy.

6. A Pharmaceutical composition containing a compound of the formula :

15

20

wherein
 R^1 is lower alkyl substituted with hydroxy, protected carboxy or carboxy; carboxy; protected carboxy; carbamoyl; a heterocyclic group; cyano; hydroxy; halo(lower)alkylsulfonyloxy; lower alkoxy optionally substituted with hydroxy or carbamoyl; aryl substituted with carboxy, protected carboxy, carbamoyl or a heterocyclic group; or amino optionally substituted with protected carboxy or lower alkylsulfonyl,

25

30

35

R^2 is hydrogen or lower alkyl,
 R^3 is aryl optionally substituted with halogen,
 R^4 is aryl optionally substituted with halogen,
Q is $-A^1 - \bigcirc - A^3 -$ [in which $-A^1-$ is a single bond or lower alkylene, \bigcirc_{A^2} is cyclo(C₅-C₉) alkene, cyclo(C₃-C₉) alkane, bicyclo(C₆-C₉) alkene or

bicyclo(C₅-C₉)alkane, and -A³⁻ is a single bond or lower alkylene], and

X is O, NH or S,
or its salt, as an active ingredient, in association
5 with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

7. A use of the compound of claim 6 as a medicament.

10 8. A use of the compound of claim 6 as an agonist or an antagonist of PGE₂-sensitive receptor.

15 9. A method for treating or preventing PGE₂ mediated diseases which comprises administering an effective amount of a compound of claim 6 to human beings or animals.

10. The method for treating or preventing inflammatory conditions, various pains, collagen diseases, autoimmune diseases, various immunity diseases, analgesic, 20 thrombosis, allergic disease, cancer or neurodegenerative diseases which comprises administering an effective amount of a compound of claim 6 to human beings or animals.

25 11. A use of a compound of claim 6 for the manufacture of a medicament for treating or preventing PGE₂ mediated diseases in human beings or animals.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 98/02398

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D263/32 C07D413/10 A61K31/42

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 03973 A (FUJISAWA PHARMACEUTICAL CO ; TANIGUCHI KIYOSHI (JP); HATTORI KOUJI) 6 February 1997 cited in the application see claims 1-5,10-14; examples 32,34 ---	1-11
X	WO 95 17393 A (FUJISAWA PHARMACEUTICAL CO ; TANIGUCHI KIYOSHI (JP); NAGANO MASANOB) 29 June 1995 cited in the application see the whole document ---	1-11
A	US 5 100 889 A (MISRA RAJ N ET AL) 31 March 1992 see the whole document -----	1-11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 August 1998

Date of mailing of the international search report

31/08/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

I. International application No.

PCT/JP 98/02398

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **9 and 10**

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 9 and 10
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.

2. Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking(Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte	nal Application No
	PCT/JP 98/02398

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9703973	A 06-02-1997	AU EP	6469796 A 0842161 A	18-02-1997 20-05-1998
WO 9517393	A 29-06-1995	AU AU CA CN EP HU JP	686286 B 1200695 A 2179399 A 1138328 A 0736018 A 76341 A 9506894 T	05-02-1998 10-07-1995 29-06-1995 18-12-1996 09-10-1996 28-08-1997 08-07-1997
US 5100889	A 31-03-1992	US AT AU AU CA CN CY DE DE DK EG EP ES FI HK HU IE IL JP MX NO PL PT SK RU	5153327 A 119903 T 632797 B 5206490 A 2012267 A 1046163 A, B 1851 A 69017735 D 69017735 T 391652 T 19080 A 0391652 A 2069682 T 97543 B 110495 A 9400057 A 67274 B 93771 A 2289579 A 20132 A 177425 B 164345 B 93641 A, B 158290 A 2059618 C	06-10-1992 15-04-1995 14-01-1993 04-10-1990 03-10-1990 17-10-1990 08-03-1996 20-04-1995 17-08-1995 03-04-1995 30-07-1994 10-10-1990 16-05-1995 30-09-1996 14-07-1995 28-04-1995 20-03-1996 29-06-1995 29-11-1990 31-01-1994 06-06-1995 29-07-1994 20-11-1990 08-04-1998 10-05-1996